{"id":12718,"date":"2026-02-17T18:46:40","date_gmt":"2026-02-17T18:46:40","guid":{"rendered":"https:\/\/csiag.de\/?p=12718"},"modified":"2026-02-17T20:56:03","modified_gmt":"2026-02-17T20:56:03","slug":"mogad-mog-antitest-asszocialt-betegseg","status":"publish","type":"post","link":"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/","title":{"rendered":"MOGAD - MOG antitestekkel \u00f6sszef\u00fcgg\u0151 betegs\u00e9g"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Tartalomjegyz\u00e9k<\/p>\n<span class=\"ez-toc-title-toggle\"><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Was_ist_MOGAD\" >Mi az a MOGAD?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Was_geht_bei_MOGAD_schief\" >Mi a baj a MOGAD-n\u00e1l?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wo_im_Korper_passiert_das\" >Hol t\u00f6rt\u00e9nik ez a testben?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wie_verlauft_die_Erkrankung\" >Hogyan fejl\u0151dik a betegs\u00e9g?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wie_haufig_ist_MOGAD\" >Mennyire gyakori a MOGAD?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Was_lost_MOGAD_aus\" >Mi v\u00e1ltja ki a MOGAD-ot?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wie_wird_MOGAD_behandelt\" >Hogyan kezelik a MOGAD-ot?<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wissenschaftliche_Einleitung_und_Definition\" >Tudom\u00e1nyos bevezet\u00e9s \u00e9s meghat\u00e1roz\u00e1s<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Abgrenzung_von_MOGAD_NMOSD_und_MS\" >A MOGAD, NMOSD \u00e9s MS k\u00f6z\u00f6tti k\u00fcl\u00f6nbs\u00e9gt\u00e9tel<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#MOG-Protein_%E2%80%93_Struktur_und_physiologische_Funktion\" >MOG feh\u00e9rje - szerkezet \u00e9s \u00e9lettani funkci\u00f3<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Strukturdomanen\" >Struktur\u00e1lis ter\u00fcletek<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Physiologische_Funktionen\" >Fiziol\u00f3giai funkci\u00f3k<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Pathogenese_und_Immunpathologie\" >Patogenezis \u00e9s immunpatol\u00f3gia<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Trigger_und_initiale_Aktivierung\" >Kiold\u00f3 \u00e9s kezdeti aktiv\u00e1l\u00e1s<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#T-Zell-vermittelte_Pathogenese\" >T-sejt k\u00f6zvet\u00edt\u00e9s\u0171 patogenezis<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_1_%E2%80%93_Periphere_Aktivierung\" >1. f\u00e1zis - Perif\u00e9ri\u00e1s aktiv\u00e1l\u00e1s<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_2_%E2%80%93_BHS-Penetration\" >2. f\u00e1zis - BHS penetr\u00e1ci\u00f3<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_3_%E2%80%93_Perivaskulare_Reaktivierung\" >3. f\u00e1zis - Perivaszkul\u00e1ris reaktiv\u00e1l\u00e1s<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#B-Zell-_und_Antikorper-vermittelte_Pathogenese\" >B-sejtek \u00e9s antitestek \u00e1ltal k\u00f6zvet\u00edtett patogenezis<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Molekulare_Signalwege_und_Effektormechanismen\" >Molekul\u00e1ris jel\u00e1tviteli utak \u00e9s hat\u00e1smechanizmusok<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalweg_1_%E2%80%93_Klassischer_Komplementweg_CDC\" >Jel\u00e1tviteli \u00fatvonal 1 - klasszikus komplement \u00fatvonal (CDC)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalweg_2_%E2%80%93_Fc%CE%B3-Rezeptor-Weg_FcR-vermittelt\" >2. jel\u00e1tviteli \u00fatvonal - Fc\u03b3 receptor \u00fatvonal (FcR-medi\u00e1lt)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalweg_3_%E2%80%93_IL-6JAK-STAT3-Weg\" >3. jel\u00e1tviteli \u00fatvonal - IL-6\/JAK-STAT3 \u00fatvonal<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalweg_4_%E2%80%93_MAPK-_und_AKT-Signalwege_B-Zellen\" >4. jel\u00e1tviteli \u00fatvonal - MAPK \u00e9s AKT jel\u00e1tviteli \u00fatvonalak (B-sejtek)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalweg_5_%E2%80%93_Th17-Zytokin-Netzwerk_im_ZNS\" >5. jel\u00e1tviteli \u00fatvonal - Th17 citokinh\u00e1l\u00f3zat a CNS-ben<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalwege_%E2%80%93_Ubersicht\" >Jel\u00e1tviteli \u00fatvonalak - \u00e1ttekint\u00e9s<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Relevante_Rezeptoren_und_Zielmolekule\" >Relev\u00e1ns receptorok \u00e9s c\u00e9lmolekul\u00e1k<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#MOG_selbst_als_Zielstruktur_kein_klassischer_Rezeptor\" >MOG maga, mint c\u00e9lstrukt\u00fara (nem klasszikus receptor)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Fc%CE%B3-Rezeptoren_Fc%CE%B3R\" >Fc\u03b3 receptorok (Fc\u03b3R)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Neonataler_Fc-Rezeptor_FcRn\" >\u00dajsz\u00fcl\u00f6ttkori Fc-receptor (FcRn)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-31\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#IL-6-Rezeptor_IL-6R%CE%B1_gp130\" >IL-6 receptor (IL-6R\u03b1 \/ gp130)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-32\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#T-Zell-Rezeptor_TCR_und_Kostimulationsmolekule\" >T-sejt receptor (TCR) \u00e9s kosztimul\u00e1ci\u00f3s molekul\u00e1k<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-33\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Komplementrezeptoren\" >Komplement receptorok<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-34\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Histopathologie_und_ZNS-Lasionsmuster\" >Hisztopatol\u00f3gia \u00e9s a CNS elv\u00e1ltoz\u00e1s mint\u00e1zata<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-35\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Klinische_Manifestationen_und_Phanotypen\" >Klinikai megnyilv\u00e1nul\u00e1sok \u00e9s fenot\u00edpusok<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-36\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Diagnostik\" >Diagnosztika<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-37\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Therapeutische_Strategien\" >Ter\u00e1pi\u00e1s strat\u00e9gi\u00e1k<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-38\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Akuttherapie_Schubbehandlung\" >Akut ter\u00e1pia (visszaes\u00e9s kezel\u00e9se)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-39\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Prophylaktische_Langzeittherapie\" >Profilaktikus hossz\u00fa t\u00e1v\u00fa ter\u00e1pia<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-40\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Klinische_Studien_%E2%80%93_2024%E2%80%932026\" >Klinikai vizsg\u00e1latok - 2024-2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-41\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Neue_und_zukunftige_Therapiekonzepte\" >\u00daj \u00e9s j\u00f6v\u0151beli ter\u00e1pi\u00e1s koncepci\u00f3k<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-42\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#BTK-Inhibitoren_Bruton-Tyrosin-Kinase\" >BTK-g\u00e1tl\u00f3k (Bruton-tirozinkin\u00e1z)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-43\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Toleranzinduktion_MOG-Tolerisierung\" >Tolerancia indukci\u00f3 (MOG-tolerancia)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-44\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Komplementinhibitoren\" >Komplement-g\u00e1tl\u00f3k<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-45\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Anti-Neonatal-Fc-Rezeptor-Strategien\" >Anti-neonatalis Fc receptor strat\u00e9gi\u00e1k<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-46\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Autologe_hamatopoetische_Stammzelltransplantation_aHSCT\" >Autol\u00f3g v\u00e9rk\u00e9pz\u0151 \u0151ssejt-transzplant\u00e1ci\u00f3 (aHSCT)<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-47\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Biomarker_und_Verlaufsmonitoring\" >Biomarkerek \u00e9s nyomon k\u00f6vet\u00e9s<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-48\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Prognose_und_Besonderheiten\" >El\u0151rejelz\u00e9s \u00e9s k\u00fcl\u00f6nlegess\u00e9gek<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-49\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Zusammenfassung_und_Ausblick\" >\u00d6sszefoglal\u00f3 \u00e9s kil\u00e1t\u00e1sok<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-50\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Atherischer_Ole_%E2%80%93_Wirkstoffe_nach_Signalwegen_geordnet\" >Ill\u00f3olajok - hat\u00f3anyagok jel\u00e1tviteli \u00fatvonalak szerint rendezve<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-51\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Weihrauch_Boswellia_serrata_%E2%80%93_AKBA_und_Incensolacetat\" >Frankincense (Boswellia serrata) - AKBA \u00e9s incensol-acet\u00e1t<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-52\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Therapeutisch_relevante_AKBA-Zieldosen\" >Ter\u00e1pi\u00e1san relev\u00e1ns AKBA c\u00e9ld\u00f3zisok<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-53\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Umrechnung_auf_375_mg_AKBA_jeKapsel\" >\u00c1tv\u00e1lt\u00e1s 37,5 mg AKBA-ra kapszul\u00e1nk\u00e9nt<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-54\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wichtige_Einnahmehinweise\" >Fontos felv\u00e9teli utas\u00edt\u00e1sok<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-55\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Schwarzer_Pfeffer_oral\" >Fekete bors (sz\u00e1jon \u00e1t)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-56\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Schwarzer_Pfeffer_Inhalation\" >Fekete bors (inhal\u00e1l\u00e1s)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-57\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Copaiba-Ol_oral_%E2%80%93_NUR_doTERRA\" >Copaiba olaj (sz\u00e1jon \u00e1t) - CSAK doTERRA<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-58\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#MOGAD-spezifische_Dosierungstabelle_doTERRA_Copaiba_525_BCP\" >MOGAD-specifikus adagol\u00e1si t\u00e1bl\u00e1zat (doTERRA Copaiba 52.5 % BCP)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-59\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#MOGAD-Phasen-adaptierte_Dosierung\" >MOGAD f\u00e1zishoz igaz\u00edtott adagol\u00e1s<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-60\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_1_Akuter_Schub_erste_2%E2%80%934_Wochen\" >1. f\u00e1zis: Akut fell\u00e1ngol\u00e1s (els\u0151 2-4 h\u00e9t)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-61\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_2_Schubremission_Erhaltung_langfristig\" >2. f\u00e1zis: visszaes\u00e9s remisszi\u00f3 \/ fenntart\u00e1s (hossz\u00fa t\u00e1v\u00fa)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-62\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_3_Monophasischer_Verlauf_Titer_fallend\" >3. f\u00e1zis: Monof\u00e1zisos k\u00fara (cs\u00f6kken\u0151 titer)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-63\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Quellen\" >Forr\u00e1sok<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-64\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Copaiba-Ol_Inhalation\" >Copaiba olaj (inhal\u00e1ci\u00f3)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-65\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Zieldosen_und_benotigte_Tropfenzahl\" >C\u00e9ladagok \u00e9s a sz\u00fcks\u00e9ges cseppek sz\u00e1ma<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-66\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Synergistische_MOGAD-Strategie_Multi-Target\" >Szinergikus MOGAD-strat\u00e9gia (t\u00f6bbc\u00e9l\u00fa)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-67\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wichtige_MOGAD-spezifische_Hinweise\" >Fontos MOGAD-specifikus inform\u00e1ci\u00f3k<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-68\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#%CE%B1-Asaron_Kalmus-Ol_Acorus_calamus_%E2%80%93_direkt_oligodendrozytenprotektiv\" >\u03b1-Asarone (calamusolaj, Acorus calamus) - k\u00f6zvetlen\u00fcl oligodendrocyta-v\u00e9d\u0151 hat\u00e1s\u00fa<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-69\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Geraniumol_Pelargonium_graveolens_%E2%80%93_Neuroinflammation_und_NO\" >Ger\u00e1niumolaj (Pelargonium graveolens) - neuroinflamm\u00e1ci\u00f3 \u00e9s NO<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-70\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Teebaum-Ol_Melaleuca_alternifolia_%E2%80%93_Mikroglia-Modulation\" >Teafaolaj (Melaleuca alternifolia) - mikroglia modul\u00e1ci\u00f3<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-71\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wirkstoffubersicht_nach_MOGAD-Signalwegen\" >A hat\u00f3anyagok \u00e1ttekint\u00e9se a MOGAD jel\u00e1tviteli \u00fatvonalak szerint<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-72\" href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Quellen_und_weiterfuhrende_Literatur\" >Forr\u00e1sok \u00e9s tov\u00e1bbi olvasnival\u00f3k<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<span class=\"span-reading-time rt-reading-time\" style=\"display: block;\"><span class=\"rt-label rt-prefix\">Olvas\u00e1si id\u0151<\/span> <span class=\"rt-time\"> 17<\/span> <span class=\"rt-label rt-postfix\">percek<\/span><\/span>\n<p><em>Myelin-oligodendrocita glikoprotein antitestekkel \u00f6sszef\u00fcgg\u0151 betegs\u00e9g<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Was_ist_MOGAD\"><\/span>Mi az a MOGAD?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Mindenki ismeri az elektromos k\u00e1beleket: Ezek szigetel\u00e9ssel vannak ell\u00e1tva, amely elv\u00e1lasztja a k\u00e1belk\u00f6tegben l\u00e9v\u0151 egyes vezet\u00e9keket egym\u00e1st\u00f3l, hogy a benn\u00fck l\u00e9v\u0151 jelek ne zavarj\u00e1k egym\u00e1st, \u00e9s torz\u00edt\u00e1smentesen jussanak el A-b\u00f3l B-be.<br>A gerincvel\u0151 sok ilyen k\u00e1belk\u00f6tegb\u0151l \u00e1ll\u00f3 eg\u00e9sz sz\u00e1lat tartalmaz. Ezek vezetik az idegjeleket az agyb\u00f3l a test k\u00fcl\u00f6nb\u00f6z\u0151 szervei, izmai, sz\u00f6vetei stb. fel\u00e9. M\u00edg a k\u00e1bel szigetel\u00e9se m\u0171anyagb\u00f3l, textilb\u0151l vagy speci\u00e1lis anyagokb\u00f3l k\u00e9sz\u00fcl, addig a gerincvel\u0151 szigetel\u0151r\u00e9tege speci\u00e1lis anyagb\u00f3l k\u00e9sz\u00fcl. <strong>Myelin r\u00e9teg<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Was_geht_bei_MOGAD_schief\"><\/span>Mi a baj a MOGAD-n\u00e1l?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>A MOGAD eset\u00e9ben a szervezet saj\u00e1t immunrendszere s\u00falyos hib\u00e1t k\u00f6vet el: t\u00e9vesen termel <strong>A szigetel\u0151r\u00e9teg k\u00fcls\u0151 oldal\u00e1n l\u00e9v\u0151 specifikus feh\u00e9rje elleni antitestek<\/strong>, Az \u00fan. <strong>MOG<\/strong>-feh\u00e9rje. Az antitestek tulajdonk\u00e9ppen a szervezet \u0151rz\u0151i, amelyek felismerik, megjel\u00f6lik \u00e9s elpuszt\u00edtj\u00e1k a k\u00f3rokoz\u00f3kat, p\u00e9ld\u00e1ul a v\u00edrusokat \u00e9s bakt\u00e9riumokat. A MOGAD-ban azonban t\u00e9vesen a szervezet saj\u00e1t eg\u00e9szs\u00e9ges sz\u00f6vete, a saj\u00e1t idegrostok szigetel\u00e9se ellen ir\u00e1nyulnak.<\/p>\n\n\n\n<p>Egy k\u00e1belhez k\u00e9pest ez olyan, mintha a szigetel\u00e9st megkarcoln\u00e1k, lehorzsoln\u00e1k vagy megrozsd\u00e1s\u00edtan\u00e1k, ami miatt az perfor\u00e1l\u00f3dik, \u00e9s az elektromos jelek m\u00e1r nem jutnak el tiszt\u00e1n vagy egy\u00e1ltal\u00e1n nem \u00e9rik el a c\u00e9ljukat.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wo_im_Korper_passiert_das\"><\/span>Hol t\u00f6rt\u00e9nik ez a testben?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>A MOGAD kiz\u00e1r\u00f3lag az al\u00e1bbiakra vonatkozik <strong>K\u00f6zponti idegrendszer<\/strong>, azaz az agy, a gerincvel\u0151 \u00e9s a l\u00e1t\u00f3idegek. Att\u00f3l f\u00fcgg\u0151en, hogy melyik ter\u00fclet \u00e9rintett, k\u00fcl\u00f6nb\u00f6z\u0151 t\u00fcnetek jelentkeznek:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>L\u00e1t\u00f3ideg<\/strong> - Hirtelen l\u00e1t\u00e1sveszt\u00e9s, hom\u00e1lyos l\u00e1t\u00e1s, szemf\u00e1jdalom (gyakran csak az egyik szemen, n\u00e9ha mindk\u00e9t szemen egyszerre - ez gyakoribb a MOGAD-ban, mint m\u00e1s hasonl\u00f3 betegs\u00e9gekben).<\/li>\n\n\n\n<li><strong>Gerincvel\u0151<\/strong> - B\u00e9nul\u00e1sos t\u00fcnetek, zsibbad\u00e1s, vizel\u00e9si probl\u00e9m\u00e1k<\/li>\n\n\n\n<li><strong>Agy :<\/strong> Zavarts\u00e1g, epilepszi\u00e1s rohamok, koordin\u00e1ci\u00f3s zavarok<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wie_verlauft_die_Erkrankung\"><\/span>Hogyan fejl\u0151dik a betegs\u00e9g?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>A MOGAD jellemz\u0151en a k\u00f6vetkez\u0151k szerint j\u00e1r el <strong>Nyomja<\/strong>. Vannak olyan f\u00e1zisok, amelyekben a gyullad\u00e1s akt\u00edv, \u00e9s a t\u00fcnetek id\u0151szakosan jelentkeznek, a kett\u0151 k\u00f6z\u00f6tt pedig csendesebb f\u00e1zisok vannak.<br>Egy-egy epiz\u00f3d ut\u00e1n sok beteg meglep\u0151en j\u00f3l gy\u00f3gyul, jobban, mint p\u00e9ld\u00e1ul az SM eset\u00e9ben. Ennek oka, hogy maguk az idegrostok gyakran kev\u00e9sb\u00e9 k\u00e1rosodnak maradand\u00f3an, mint a szigetel\u0151r\u00e9teg, amely r\u00e9szben regener\u00e1l\u00f3dhat.<\/p>\n\n\n\n<p>Az \u00e9rintettek mintegy fel\u00e9n\u00e9l \u00e9let\u00fck sor\u00e1n csak egyetlen fell\u00e1ngol\u00e1s fordul el\u0151. A m\u00e1sik fel\u00e9nek visszat\u00e9r\u0151 epiz\u00f3djai vannak, amelyek kezeletlen\u00fcl maradva maradand\u00f3 k\u00e1rosod\u00e1shoz vezethetnek.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wie_haufig_ist_MOGAD\"><\/span>Mennyire gyakori a MOGAD?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>A MOGAD ritka, csak becsl\u00e9sek szerint <strong>1-2 a 100,000 emberb\u0151l<\/strong> megbetegszik. Az idegrendszer sz\u00e1mos m\u00e1s autoimmun betegs\u00e9g\u00e9t\u0151l elt\u00e9r\u0151en ez a betegs\u00e9g nagyj\u00e1b\u00f3l egyenl\u0151 ar\u00e1nyban \u00e9rinti a n\u0151ket \u00e9s a f\u00e9rfiakat. Gyermekekn\u00e9l is kialakulhat a betegs\u00e9g, amely gyakran az agy kiterjedt, zavarts\u00e1ggal \u00e9s l\u00e1zzal j\u00e1r\u00f3 gyullad\u00e1sak\u00e9nt jelentkezik.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Was_lost_MOGAD_aus\"><\/span>Mi v\u00e1ltja ki a MOGAD-ot?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Az els\u0151 epiz\u00f3dot gyakran k\u00f6veti <strong>Fert\u0151z\u00e9s<\/strong> el\u0151re. A szervezet harcol a k\u00f3rokoz\u00f3 ellen, \u00e9s t\u00e9vesen \u00f6sszekeveri a szervezet saj\u00e1t strukt\u00far\u00e1it az ellens\u00e9ggel. Az immunrendszer megtanulja, hogy \u00fagymond rossz c\u00e9lpontot t\u00e1madjon, \u00e9s soha nem \u00e1ll le. A pontos ok m\u00e9g nem teljesen tiszt\u00e1zott. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wie_wird_MOGAD_behandelt\"><\/span>Hogyan kezelik a MOGAD-ot?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Jelenleg nincs kifejezetten a MOGAD-ra enged\u00e9lyezett gy\u00f3gyszeres kezel\u00e9s. One <strong>akut t\u00e1mad\u00e1s<\/strong> nagy d\u00f3zis\u00fa <strong>Kortizon inf\u00fazi\u00f3k<\/strong>, amelyek gyorsan csillap\u00edtj\u00e1k a gyullad\u00e1st. Ha ez nem elegend\u0151 <strong>V\u00e9rmos\u00e1s<\/strong> (<em>Plazmaferezis<\/em>) a k\u00e1ros antitest k\u00f6zvetlen\u00fcl a v\u00e9rb\u0151l t\u00e1vol\u00edthat\u00f3 el.<\/p>\n\n\n\n<p>A <strong>A tov\u00e1bbi visszaes\u00e9sek megel\u0151z\u00e9se<\/strong> Az immunrendszer nyugtat\u00e1s\u00e1ra k\u00fcl\u00f6nb\u00f6z\u0151 gy\u00f3gyszereket haszn\u00e1lnak, p\u00e9ld\u00e1ul olyan anyagokkal, amelyek cs\u00f6kkentik az antitesttermel\u0151 sejtek sz\u00e1m\u00e1t. Jelenleg t\u00f6bb \u00faj, c\u00e9lzottabb gy\u00f3gyszert tesztelnek klinikai vizsg\u00e1latokban, \u00e9s a k\u00f6vetkez\u0151 n\u00e9h\u00e1ny \u00e9vben enged\u00e9lyezhetik \u0151ket.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wissenschaftliche_Einleitung_und_Definition\"><\/span>Tudom\u00e1nyos bevezet\u00e9s \u00e9s meghat\u00e1roz\u00e1s<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p>A <strong>MOG antitestekkel \u00f6sszef\u00fcgg\u0151 betegs\u00e9g (MOGAD)<\/strong> Angolul: <em>Myelin-oligodendrocita glikoprotein antitestekkel \u00f6sszef\u00fcgg\u0151 betegs\u00e9g<\/em> a k\u00f6zponti idegrendszer (CNS) ritka, gyullad\u00e1sos autoimmun betegs\u00e9ge, amelyet 2018 \u00f3ta \u00f6n\u00e1ll\u00f3 entit\u00e1sk\u00e9nt, saj\u00e1t diagnosztikai krit\u00e9riumokkal ismerik el. Kor\u00e1bban a szkler\u00f3zis multiplex (MS) egyik v\u00e1ltozat\u00e1nak vagy neuromyelitis optica spektrumzavarnak (NMOSD) tekintett\u00e9k.<\/p>\n\n\n\n<p>A betegs\u00e9g k\u00f6zponti eleme az autoantitestek (IgG) k\u00f3ros termel\u0151d\u00e9se a <strong>Myelin oligodendrocyta glikoprotein (MOG)<\/strong>, transzmembr\u00e1nfeh\u00e9rje, amely az oligodendrocit\u00e1k myelinh\u00fcvely\u00e9nek legk\u00fcls\u0151 r\u00e9teg\u00e9n tal\u00e1lhat\u00f3 a k\u00f6zponti idegrendszerben. Ezek az antitestek k\u00e1ros\u00edtj\u00e1k a mielinh\u00fcvelyt, \u00e9s jellegzetes perivenul\u00e1ris demieliniz\u00e1ci\u00f3hoz vezetnek.<\/p>\n\n\n\n<p>Klinikailag a MOGAD els\u0151sorban optikai neuritisz, har\u00e1ntir\u00e1ny\u00fa myelitisz \u00e9s akut disszemin\u00e1lt encephalomyelitis (ADEM) form\u00e1j\u00e1ban jelentkezik. A betegs\u00e9g \u00e1ltal\u00e1ban visszaes\u0151, \u00e9s a l\u00e1t\u00f3ideget, a gerincvel\u0151t, ritk\u00e1bban az agyat \u00e9rinti. A betegs\u00e9g kezdet\u00e9nek \u00e1tlag\u00e9letkora 30 \u00e9s 35 \u00e9v k\u00f6z\u00f6tt van; az NMOSD-vel ellent\u00e9tben a n\u0151k \u00e9s a f\u00e9rfiak szinte egyform\u00e1n gyakran \u00e9rintettek.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Abgrenzung_von_MOGAD_NMOSD_und_MS\"><\/span>A MOGAD, NMOSD \u00e9s MS k\u00f6z\u00f6tti k\u00fcl\u00f6nbs\u00e9gt\u00e9tel<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Jellemz\u0151<\/strong><\/td><td><strong>MOGAD<\/strong><\/td><td><strong>AQP4+ NMOSD<\/strong><\/td><td><strong>Sclerosis multiplex<\/strong><\/td><\/tr><\/thead><tbody><tr><td>C\u00e9lzott antig\u00e9n<\/td><td>MOG (oligodendrocit\u00e1k)<\/td><td>Aquaporin-4 (asztrocit\u00e1k)<\/td><td>Nincs specifikus autoantitest<\/td><\/tr><tr><td>Antitest izot\u00edpus<\/td><td>IgG1 (pre)<\/td><td>IgG1 (pre)<\/td><td>Oligoklon\u00e1lis IgG (CSF)<\/td><\/tr><tr><td>Els\u0151dleges sejtk\u00e1rosod\u00e1s<\/td><td>Oligodendrocit\u00e1k\/myelin<\/td><td>Asztrocit\u00e1k (els\u0151dleges)<\/td><td>Oligodendrocit\u00e1k<\/td><\/tr><tr><td>Histol\u00f3gia<\/td><td>Perivenularis demyeliniz\u00e1ci\u00f3, CD4+<\/td><td>Asztrocita elv\u00e1ltoz\u00e1sok, granulocit\u00e1k<\/td><td>Periaxi\u00e1lis plakkok<\/td><\/tr><tr><td>Nem (F:M)<\/td><td>~1:1<\/td><td>~9:1<\/td><td>~3:1<\/td><\/tr><tr><td>Komplement aktiv\u00e1l\u00e1s<\/td><td>M\u00e9rs\u00e9kelt (kevesebb MAC)<\/td><td>Er\u0151s (MAC-alakzat)<\/td><td>Alacsony<\/td><\/tr><tr><td>OKB az agy-gerincvel\u0151i folyad\u00e9kban<\/td><td>Ritka (&lt;10%)<\/td><td>Alkalmank\u00e9nt<\/td><td>Gyakori (&gt;90%)<\/td><\/tr><tr><td>Tanfolyam<\/td><td>Visszat\u00e9r\u0151; gyakran j\u00f3l gy\u00f3gyul\u00f3<\/td><td>Tol\u00f3 alak\u00fa; halmoz\u00f3dik a fogyat\u00e9koss\u00e1g<\/td><td>Gyakran progedient<\/td><\/tr><tr><td>Enged\u00e9lyezett ter\u00e1pi\u00e1k<\/td><td>Nincs (2026-t\u00f3l)<\/td><td>Eculizumab, ublituximab, satralizumab<\/td><td>Sok DMT<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"MOG-Protein_%E2%80%93_Struktur_und_physiologische_Funktion\"><\/span>MOG feh\u00e9rje - szerkezet \u00e9s \u00e9lettani funkci\u00f3<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p>A MOG (myelin oligodendrocyte glycoprotein) egy <strong>I-es t\u00edpus\u00fa transzmembr\u00e1n feh\u00e9rje<\/strong> amelynek teljes hossza 218 aminosav, \u00e9s amely kiz\u00e1r\u00f3lag a k\u00f6zponti idegrendszerben fejez\u0151dik ki. Az immunglobulin szupercsal\u00e1d tagja, \u00e9s a teljes mielinfeh\u00e9rje 0,01-0,05 % k\u00f6r\u00fcli ar\u00e1ny\u00e1val a mielinh\u00fcvely mennyis\u00e9gileg kicsi, de immunol\u00f3giailag igen fontos \u00f6sszetev\u0151je.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Strukturdomanen\"><\/span>Struktur\u00e1lis ter\u00fcletek<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Extracellul\u00e1ris Ig-V-szer\u0171 dom\u00e9n (AS 1-120): Egyetlen expon\u00e1lt dom\u00e9n, er\u0151sen immunog\u00e9n; tartalmazza a kritikus CC\u2018 hurok r\u00e9gi\u00f3t (Pro42, His103, Ser104), amely a MOG-IgG legfontosabb epit\u00f3pk\u00f6t\u0151 helye.<\/li>\n\n\n\n<li>Egyutas transzmembr\u00e1n h\u00e9lix: lehorgonyozza a feh\u00e9rj\u00e9t a mielinmembr\u00e1nban.<\/li>\n\n\n\n<li>R\u00f6vid citoplazmatikus C-termin\u00e1lis dom\u00e9n: val\u00f3sz\u00edn\u0171leg k\u00f6lcs\u00f6nhat\u00e1sba l\u00e9p a citoszkelettel.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Physiologische_Funktionen\"><\/span>Fiziol\u00f3giai funkci\u00f3k<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Adh\u00e9zi\u00f3s molekula: A myelinh\u00fcvely szerkezeti integrit\u00e1s\u00e1t k\u00f6zvet\u00edti, val\u00f3sz\u00edn\u0171leg a myelin lamell\u00e1k t\u00f6m\u00f6r\u00edt\u00e9s\u00e9vel.<\/li>\n\n\n\n<li>Interakci\u00f3 a komplementrendszer C1q-j\u00e1val (fiziol\u00f3giai)<\/li>\n\n\n\n<li>Interakci\u00f3 az idegi n\u00f6veked\u00e9si faktorral (NGF)<\/li>\n\n\n\n<li>A rubeolav\u00edrus receptora (klinikailag relev\u00e1ns a poszt-infekt\u00edv ADEM szempontj\u00e1b\u00f3l)<\/li>\n\n\n\n<li>A mikrotubulusok stabiliz\u00e1l\u00e1sa az oligodendrocit\u00e1kban<\/li>\n\n\n\n<li>Kifejez\u0151d\u00e9s: Az oligodendrocita differenci\u00e1l\u00f3d\u00e1s v\u00e9g\u00e9n; csak a kezdeti myeliniz\u00e1ci\u00f3 ut\u00e1n.<\/li>\n<\/ul>\n\n\n\n<p>A MOG-IgG autoantitestek els\u0151sorban a k\u00f6vetkez\u0151 anyagokat ismerik fel <strong>Konform\u00e1ci\u00f3s epit\u00f3pok<\/strong> az extracellul\u00e1ris dom\u00e9n. Mivel a MOG a myelinh\u00fcvely legk\u00fcls\u0151 felsz\u00edn\u00e9n van, k\u00f6zvetlen\u00fcl hozz\u00e1f\u00e9rhet\u0151 a kering\u0151 antitestek \u00e9s immunkomplexek sz\u00e1m\u00e1ra - ami d\u00f6nt\u0151 k\u00fcl\u00f6nbs\u00e9g az intracellul\u00e1ris antig\u00e9nekhez k\u00e9pest.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Pathogenese_und_Immunpathologie\"><\/span>Patogenezis \u00e9s immunpatol\u00f3gia<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p>A MOGAD patogenezise egy t\u00f6bbl\u00e9pcs\u0151s folyamat, amely mag\u00e1ban foglalja a perif\u00e9ri\u00e1s immunrendszer aktiv\u00e1l\u00f3d\u00e1s\u00e1t, a v\u00e9r-agy g\u00e1ton (BBB) kereszt\u00fcli migr\u00e1ci\u00f3t \u00e9s a CNS-lok\u00e1lis hat\u00e1smechanizmusokat. Sem a T-sejtek, sem a B-sejtek \u00f6nmagukban nem el\u00e9gg\u00e9 patog\u00e9n hat\u00e1s\u00faak, a betegs\u00e9get az adapt\u00edv immunrendszer mindk\u00e9t \u00e1g\u00e1nak szinergikus k\u00f6lcs\u00f6nhat\u00e1sa okozza.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Trigger_und_initiale_Aktivierung\"><\/span>Kiold\u00f3 \u00e9s kezdeti aktiv\u00e1l\u00e1s<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>A f\u0151 kezdeti kiv\u00e1lt\u00f3 okok a k\u00f6vetkez\u0151k <strong>Fert\u0151z\u00e9sek<\/strong> megvitatt\u00e1k: A MOGAD-betegek 37-70 %-j\u00e9n\u00e9l dokument\u00e1lt\u00e1k a fert\u0151z\u00e9ses prodrom\u00e1t (ez gyakoribb, mint a 15-35 %-j\u0171 NMOSD-ben). A mechanizmusok k\u00f6z\u00e9 tartoznak:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Molekul\u00e1ris mimikri - a k\u00f3rokoz\u00f3 epit\u00f3pok szerkezetileg hasonl\u00f3ak a MOG CC\u2018 hurok r\u00e9gi\u00f3j\u00e1hoz, pl. SARS-CoV-2 szekvenci\u00e1k vagy rubeolav\u00edrusok.<\/li>\n\n\n\n<li>Bystander aktiv\u00e1ci\u00f3 - a nem specifikus gyullad\u00e1sos reakci\u00f3 aktiv\u00e1lja a nyugv\u00f3 autoreakt\u00edv limfocit\u00e1kat.<\/li>\n\n\n\n<li>Poliklon\u00e1lis B-sejt-aktiv\u00e1ci\u00f3 mikrobi\u00e1lis szuperantig\u00e9nekkel<\/li>\n<\/ul>\n\n\n\n<p>A genetikai hajlam szerepet j\u00e1tszik, de a specifikus kock\u00e1zati haplot\u00edpusokat nem siker\u00fclt egy\u00e9rtelm\u0171en azonos\u00edtani. A szkler\u00f3zis multiplexszel ellent\u00e9tben nem \u00edrtak le k\u00f6vetkezetes HLA \u00f6sszef\u00fcgg\u00e9seket.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"T-Zell-vermittelte_Pathogenese\"><\/span>T-sejt k\u00f6zvet\u00edt\u00e9s\u0171 patogenezis<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>A MOG-specifikus CD4+ T-sejtek n\u00e9lk\u00fcl\u00f6zhetetlenek a MOGAD patogenezis\u00e9ben. \u00c1llati modellekben (EAE) az antitestek \u00f6nmagukban nem patog\u00e9n hat\u00e1s\u00faak; sz\u00fcks\u00e9g van enkefalitog\u00e9n T-sejtekre, mint t\u00e1rshat\u00e1s\u00fa sejtekre. A CD4+ \u00fatvonal t\u00f6bb f\u00e1zisb\u00f3l \u00e1ll:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_1_%E2%80%93_Periphere_Aktivierung\"><\/span>1. f\u00e1zis - Perif\u00e9ri\u00e1s aktiv\u00e1l\u00e1s<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>A MOG peptideket az antig\u00e9nprezent\u00e1l\u00f3 sejtek (APC) termelik a k\u00f6vetkez\u0151 m\u00f3don <strong>MHC-II molekul\u00e1k<\/strong> a naiv CD4+ T-sejtekhez. Figyelemre m\u00e9lt\u00f3: <em>A MOG peptidek k\u00f6zvetlen\u00fcl k\u00f6t\u0151dhetnek a perif\u00e9ri\u00e1s MHC II molekul\u00e1khoz.<\/em>, tov\u00e1bbi feldolgoz\u00e1s n\u00e9lk\u00fcl. Ez magyar\u00e1zatot adhat a perif\u00e9ri\u00e1s idegrendszer bevon\u00e1s\u00e1ra.<\/p>\n\n\n\n<p>Az egym\u00e1st\u00f3l f\u00fcggetlen\u00fcl EAE-t kiv\u00e1ltani k\u00e9pes effektorsejt-alcsoportok a k\u00f6vetkez\u0151k <strong>Th1, Th17 \u00e9s Th9<\/strong>. A Th17 sejtek k\u00fcl\u00f6n\u00f6sen fontosak a MOGAD szempontj\u00e1b\u00f3l, mivel a Th17 citokinek (IL-17, IL-21) jelent\u0151sen emelkednek a ny\u00edr\u00e1si epiz\u00f3dok sor\u00e1n.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_2_%E2%80%93_BHS-Penetration\"><\/span>2. f\u00e1zis - BHS penetr\u00e1ci\u00f3<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Az aktiv\u00e1lt CD4+ T-sejtek specifikus adh\u00e9zi\u00f3s molekul\u00e1kat (integrinek, szelektinek) \u00e9s kemokin receptorokat (k\u00fcl\u00f6n\u00f6sen <strong>CCR6<\/strong>), amelyek lehet\u0151v\u00e9 teszik sz\u00e1mukra a CNS-be val\u00f3 bejut\u00e1st. A CCR6+ Th17 sejtek a CCL20-hoz k\u00f6t\u0151dnek, amely konstitut\u00edvan expressz\u00e1l\u00f3dik a plexus chorioideusban, \u00e9s azon kereszt\u00fcl jutnak be a subarachnoide\u00e1lis t\u00e9rbe.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>M\u00e1trix metalloprotein\u00e1zok (MMP-2, MMP-9)<br>A BBB b\u00e1zismembr\u00e1nj\u00e1nak degrad\u00e1ci\u00f3ja<\/li>\n\n\n\n<li>Neutrofil NET-ek (neutrofil extracellul\u00e1ris csapd\u00e1k)<br>Kosztimul\u00e1l\u00f3 jeleket szolg\u00e1ltatnak a T-sejtek sz\u00e1m\u00e1ra a beindul\u00e1si f\u00e1zisban.<\/li>\n\n\n\n<li>Trombocit\u00e1k<br>A CD4+ T-sejtek prolifer\u00e1ci\u00f3j\u00e1nak \u00e9s Th1\/Th17 differenci\u00e1l\u00f3d\u00e1s\u00e1nak el\u0151seg\u00edt\u00e9se citokinek \u00e9s adh\u00e9zi\u00f3s molekul\u00e1k r\u00e9v\u00e9n.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_3_%E2%80%93_Perivaskulare_Reaktivierung\"><\/span>3. f\u00e1zis - Perivaszkul\u00e1ris reaktiv\u00e1l\u00e1s<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>A perivascularis t\u00e9rben \u00e9s a subarachnoidalis t\u00e9rben a MOG-specifikus T-sejteket a helyi MOG-gal terhelt APC-k (mikroglia, dendritikus sejtek) reaktiv\u00e1lj\u00e1k. Ez a reaktiv\u00e1ci\u00f3 ind\u00edtja el a t\u00e9nyleges gyullad\u00e1sos kaszk\u00e1dot: Proinflammatorikus citokinek szekr\u00e9ci\u00f3ja, tov\u00e1bbi leukocit\u00e1k toborz\u00e1sa \u00e9s oligodendrocita k\u00e1rosod\u00e1s.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"B-Zell-_und_Antikorper-vermittelte_Pathogenese\"><\/span>B-sejtek \u00e9s antitestek \u00e1ltal k\u00f6zvet\u00edtett patogenezis<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>A MOG-specifikus B-sejtek \u00e9s plazmasejtek a patog\u00e9n IgG1 autoantitestek f\u0151 termel\u0151i. A B-sejtek szerepe azonban t\u00falmutat az antitesttermel\u00e9sen:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Antig\u00e9nprezent\u00e1ci\u00f3 - a B-sejtek k\u00e9pesek a MOG konform\u00e1ci\u00f3s epit\u00f3pjait (pro42, his103, ser104 a CC\u2018 hurokban) BCR-j\u00fck\u00f6n kereszt\u00fcl megk\u00f6tni, \u00e9s APC-k\u00e9nt viselkednek a T-sejtek sz\u00e1m\u00e1ra.<\/li>\n\n\n\n<li>A Th17 differenci\u00e1l\u00f3d\u00e1s el\u0151seg\u00edt\u00e9se - A B-sejtek IL-6-ot v\u00e1lasztanak ki, amely a TGF-\u03b2-vel egy\u00fctt a Th17 differenci\u00e1l\u00f3d\u00e1st seg\u00edti el\u0151.<\/li>\n\n\n\n<li>MAPK \u00e9s AKT jel\u00e1tviteli aktiv\u00e1ci\u00f3 - a BCR k\u00f6t\u0151d\u00e9se a MOG-hoz intracellul\u00e1risan aktiv\u00e1lja ezeket a jel\u00e1tviteli utakat.<\/li>\n\n\n\n<li>Az intracellul\u00e1ris kalciumszint emelked\u00e9se - A stresszel kapcsolatos jel\u00e1tviteli kaszk\u00e1dok aktiv\u00e1l\u00f3d\u00e1s\u00e1hoz vezet.<\/li>\n<\/ul>\n\n\n\n<p>A legt\u00f6bb MOG-IgG antitest a perif\u00e9ri\u00e1n termel\u0151dik (oligoklon\u00e1lis s\u00e1vok a liquorban csak az esetek ~10 %-\u00e9ben, \u00f6sszehasonl\u00edt\u00e1sk\u00e9ppen: MS ~90 %). Az antitestek <strong>k\u00e9t\u00e9rt\u00e9k\u0171 k\u00f6t\u0151d\u00e9s<\/strong> a MOG-hoz, mindk\u00e9t Fab-kar egyszerre k\u00f6t\u0151dik k\u00e9t szomsz\u00e9dos MOG-molekul\u00e1hoz. Ez az AQP4-IgG monovalens k\u00f6t\u0151d\u00e9s\u00e9hez k\u00e9pest kev\u00e9sb\u00e9 hat\u00e9kony C1q-rekrimin\u00e1ci\u00f3hoz vezet az NMOSD-ben.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Molekulare_Signalwege_und_Effektormechanismen\"><\/span>Molekul\u00e1ris jel\u00e1tviteli utak \u00e9s hat\u00e1smechanizmusok<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalweg_1_%E2%80%93_Klassischer_Komplementweg_CDC\"><\/span>Jel\u00e1tviteli \u00fatvonal 1 - klasszikus komplement \u00fatvonal (CDC)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Ha a MOG-IgG1 (\u00e9s a MOG-IgG3) k\u00f6t\u0151dik az oligodendrocyta MOG-hoz, akkor a MOG-IgG1 (\u00e9s a MOG-IgG3) <strong>klasszikus kieg\u00e9sz\u00edt\u0151 \u00fatvonal<\/strong> aktiv\u00e1l\u00f3dnak. A komplementaktiv\u00e1ci\u00f3 azonban a MOGAD-ban gyeng\u00e9bb, mint az AQP4+ NMOSD-ben:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>C1q k\u00f6t\u0151d\u00e9s a k\u00f6t\u00f6tt IgG1 antitestek Fc r\u00e9sz\u00e9hez \u2192 C1r \u00e9s C1s aktiv\u00e1l\u00e1sa<\/li>\n\n\n\n<li>C4 hasad\u00e1sa \u2192 C4a + C4b; C4b + C2 \u2192 C3 konvert\u00e1z (C4b2a)<\/li>\n\n\n\n<li>C3 hasad\u00e1sa \u2192 C3a (anafilatoxin) + C3b (opsonin)<\/li>\n\n\n\n<li>C3b \u2192 C5-konvert\u00e1z \u2192 C5 has\u00edt\u00e1sa \u2192 C5a (er\u0151s anafilatoxin) + C5b<\/li>\n\n\n\n<li>C5b + C6, C7, C8, C9 \u2192 membr\u00e1nt\u00e1mad\u00f3 komplex (MAC, C5b-9): Az oligodendrocit\u00e1k k\u00f6zvetlen l\u00edzise.<\/li>\n<\/ul>\n\n\n\n<p>Fontos: A MOGAD betegek liquorj\u00e1ban a C3a \u00e9s a C5a szignifik\u00e1nsan emelkedett (hasonl\u00f3an az AQP4+ NMOSD-hez), de a MAC-komplex (C5b-9) nem emelkedett szignifik\u00e1nsan. <strong>jelent\u0151sen alacsonyabb<\/strong> mint az NMOSD-ben. Ez a k\u00e9t\u00e9rt\u00e9k\u0171 IgG-k\u00f6t\u0151d\u00e9snek k\u00f6sz\u00f6nhet\u0151, amely kev\u00e9sb\u00e9 hat\u00e9kony a C1q klaszterez\u0151d\u00e9se szempontj\u00e1b\u00f3l, valamint a komplementszab\u00e1lyoz\u00f3k viszonylag alacsony s\u0171r\u0171s\u00e9g\u00e9nek az oligodendrocit\u00e1kon (kevesebb CR1, MCP, HRF, mint m\u00e1s sejtt\u00edpusokon).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalweg_2_%E2%80%93_Fc%CE%B3-Rezeptor-Weg_FcR-vermittelt\"><\/span>2. jel\u00e1tviteli \u00fatvonal - Fc\u03b3 receptor \u00fatvonal (FcR-medi\u00e1lt)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Az LMU kutat\u00e1sai (Mader, Kawakami, Meinl, 2024 PNAS) kimutatt\u00e1k, hogy az Fc\u03b3 receptor (Fc\u03b3R) \u00e1ltal k\u00f6zvet\u00edtett mechanizmusok <strong>k\u00f6r\u00fclbel\u00fcl 50 % myelink\u00e1rosod\u00e1sra<\/strong> \u00e9s ez\u00e9rt egyenrang\u00faak a komplement aktiv\u00e1l\u00e1s\u00e1val:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Fc\u03b3RIII<\/strong> (<strong>CD16<\/strong>) az NK-sejtekre \u00e9s makrof\u00e1gokra<br>Megk\u00f6ti a MOG-hez k\u00f6t\u00f6tt IgG1 Fc r\u00e9sz\u00e9t \u2192 ADCC (antitest-f\u00fcgg\u0151 cellul\u00e1ris citotoxicit\u00e1s)<\/li>\n\n\n\n<li><strong>Fc\u03b3RI\/II\/III<\/strong> makrof\u00e1gokon \u00e9s monocit\u00e1kon<br>MOG-opszoniz\u00e1lt oligodendrocita fragmentumok fagocit\u00f3zisa (ADCP)<\/li>\n\n\n\n<li>D\u00f6nt\u0151: A m\u00e1sodik FcR patomechanizmus<br>A T-sejtek aktiv\u00e1l\u00f3d\u00e1s\u00e1nak fokoz\u00e1sa, kiz\u00e1r\u00f3lag az Fc-receptorokon kereszt\u00fcl, NEM a komplement \u00fatvonalon kereszt\u00fcl t\u00f6rt\u00e9nik<\/li>\n\n\n\n<li><strong>Fc\u03b3R<\/strong> a dendritikus sejtekr\u0151l<br>A MOG-IgG-vel t\u00f6lt\u00f6tt oligodendrocita antig\u00e9nek MOG-specifikus T-sejtek sz\u00e1m\u00e1ra t\u00f6rt\u00e9n\u0151 feldolgoz\u00e1s\u00e1nak \u00e9s prezent\u00e1ci\u00f3j\u00e1nak el\u0151seg\u00edt\u00e9se.<\/li>\n<\/ul>\n\n\n\n<p>Klinikai k\u00f6vetkezm\u00e9ny: Mivel k\u00e9t f\u00fcggetlen patog\u00e9n \u00fatvonal l\u00e9tezik, a ter\u00e1pi\u00e1s megk\u00f6zel\u00edt\u00e9seket \u00fagy kell kialak\u00edtani, hogy <strong>Mindk\u00e9t mechanizmus<\/strong> a maxim\u00e1lis hat\u00e9konys\u00e1g el\u00e9r\u00e9se \u00e9rdek\u00e9ben.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalweg_3_%E2%80%93_IL-6JAK-STAT3-Weg\"><\/span>3. jel\u00e1tviteli \u00fatvonal - IL-6\/JAK-STAT3 \u00fatvonal<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Az IL-6 a MOGAD immunpatogenezis k\u00f6zponti k\u00f6zvet\u00edt\u0151je, \u00e9s t\u00f6bb szinten is hat:<\/p>\n\n\n\n<p>Az IL-6 k\u00f6t\u0151dik a receptor\u00e1hoz (IL-6R\u03b1\/gp130 komplex), ami az IL-6 \u00e9s a <strong>JAK1\/2 foszforil\u00e1ci\u00f3<\/strong> vezet. Ez els\u0151sorban a <strong>STAT3<\/strong>, amely transzkripci\u00f3s faktork\u00e9nt szolg\u00e1l:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Th17 differenci\u00e1l\u00f3d\u00e1s<\/strong><br>IL-6 + TGF-\u03b2 \u2192 ROR\u03b3t expresszi\u00f3 \u2192 IL-17A\/F termel\u00e9s; IL-6 + IL-23 \u2192 a Th17 fenot\u00edpus fenntart\u00e1sa.<\/li>\n\n\n\n<li><strong>Folicular T helper sejtek<\/strong> (<strong>Tfh<\/strong>)<br>IL-6 \u2192 STAT3 \u2192 Bcl6 expresszi\u00f3 \u2192 cs\u00edrak\u00f6zponti B-sejt \u00e9r\u00e9s \u00e9s IgG oszt\u00e1lyv\u00e1lt\u00e1s<\/li>\n\n\n\n<li><strong>B-sejtek \u00e9r\u00e9se plazmasejtekk\u00e9<\/strong><br>Az IL-6 el\u0151seg\u00edti a differenci\u00e1l\u00f3d\u00e1st a STAT3\/Blimp-1 tengelyen kereszt\u00fcl<\/li>\n\n\n\n<li><strong>A Treg funkci\u00f3 elnyom\u00e1sa<\/strong><br>Az IL-6 g\u00e1tolja a FoxP3 expresszi\u00f3j\u00e1t, ami a Treg\/Th17 egyens\u00falyt a gyullad\u00e1s ir\u00e1ny\u00e1ba tolja el.<\/li>\n<\/ul>\n\n\n\n<p>Ter\u00e1pi\u00e1s jelent\u0151s\u00e9g: IL-6-blok\u00e1d (pl. tocilizumab, szatralizumab) megt\u00f6ri ezt a ciklust. <strong><em>Satralizumab<\/em><\/strong> (anti-IL-6R) jelenleg a METEOROID 3. f\u00e1zis\u00fa vizsg\u00e1latban vizsg\u00e1lj\u00e1k a MOGAD eset\u00e9ben.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalweg_4_%E2%80%93_MAPK-_und_AKT-Signalwege_B-Zellen\"><\/span>4. jel\u00e1tviteli \u00fatvonal - MAPK \u00e9s AKT jel\u00e1tviteli \u00fatvonalak (B-sejtek)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>A BCR k\u00f6t\u0151d\u00e9se a B-sejtekben aktiv\u00e1lt MOG konform\u00e1ci\u00f3s epit\u00f3pokhoz:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MAPK \u00fatvonal<\/strong> (<strong>MEK\/ERK<\/strong>)<br>A B-sejtek prolifer\u00e1ci\u00f3j\u00e1nak \u00e9s differenci\u00e1l\u00f3d\u00e1s\u00e1nak el\u0151seg\u00edt\u00e9se<\/li>\n\n\n\n<li><strong>PI3K\/AKT \u00fatvonal<\/strong><br>A B-sejtek t\u00fal\u00e9l\u00e9se \u00e9s differenci\u00e1l\u00f3d\u00e1sa plazmasejtekk\u00e9<\/li>\n\n\n\n<li><strong>Kalcium be\u00e1raml\u00e1s<\/strong><br>A kalcineurin\/NFAT tengely aktiv\u00e1l\u00e1sa \u2192 Citokintermel\u00e9s<\/li>\n\n\n\n<li><strong>NK sejtek aktiv\u00e1l\u00e1sa<\/strong><br>A BCR-MOG k\u00f6t\u0151d\u00e9s NK-sejt-medi\u00e1lt citotoxicit\u00e1st induk\u00e1l<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalweg_5_%E2%80%93_Th17-Zytokin-Netzwerk_im_ZNS\"><\/span>5. jel\u00e1tviteli \u00fatvonal - Th17 citokinh\u00e1l\u00f3zat a CNS-ben<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>A CNS-ben a Th17 sejtek t\u00f6bb medi\u00e1toron kereszt\u00fcl tartj\u00e1k fenn a gyullad\u00e1sos k\u00f6rnyezetet:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IL-17A \u00e9s IL-17F<\/strong><br>Asztrocit\u00e1k \u00e9s mikroglia aktiv\u00e1l\u00e1sa; neutrofileket toborz\u00f3 kemokinek (CXCL-1\/5\/8) felszabadul\u00e1s\u00e1t induk\u00e1lja.<\/li>\n\n\n\n<li><strong>IL-21<\/strong> (auto- \u00e9s parakrin)<br>Fokozza a Th17 differenci\u00e1l\u00f3d\u00e1st; el\u0151seg\u00edti a B-sejtek differenci\u00e1l\u00f3d\u00e1s\u00e1t \u00e9s az IgG oszt\u00e1lyv\u00e1lt\u00e1st (k\u00fcl\u00f6n\u00f6sen az IgG1-et).<\/li>\n\n\n\n<li><strong>IL-22<\/strong><br>A BBB integrit\u00e1s\u00e1nak diszregul\u00e1ci\u00f3ja<\/li>\n\n\n\n<li><strong>GM-CSF<\/strong> (<strong>az IL-23-on kereszt\u00fcl<\/strong>)<br>Aktiv\u00e1lja a mikroglia \u00e9s a makrof\u00e1gok m\u0171k\u00f6d\u00e9s\u00e9t, fokozza a helyi demielin\u00e1ci\u00f3t.<\/li>\n\n\n\n<li><strong>CXCL13<\/strong><br>B-sejtek kemotaxisa a perivaszkul\u00e1ris terekben \u2192 helyi antitesttermel\u00e9s<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalwege_%E2%80%93_Ubersicht\"><\/span>Jel\u00e1tviteli \u00fatvonalak - \u00e1ttekint\u00e9s<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Jel\u00fatvonal<\/strong><\/td><td><strong>Kulcsmolekul\u00e1k<\/strong><\/td><td><strong>Hat\u00e1s<\/strong><\/td><td><strong>Ter\u00e1pi\u00e1s c\u00e9lpontok<\/strong><\/td><\/tr><\/thead><tbody><tr><td>Klasszikus kieg\u00e9sz\u00edt\u0151 \u00fatvonal<\/td><td>C1q, C3, C5, MAC (C5b-9)<\/td><td>K\u00f6zvetlen oligodendrocita l\u00edzis<\/td><td>C5-g\u00e1tl\u00f3k (eculizumab), C3-g\u00e1tl\u00f3k<\/td><\/tr><tr><td>Fc\u03b3R \u00fatvonal (ADCC\/ADCP)<\/td><td>Fc\u03b3RI\/II\/III, NK sejtek, makrof\u00e1gok<\/td><td>Citotoxicit\u00e1s, fagocit\u00f3zis, T-sejt-potenci\u00e1l\u00e1s<\/td><td>FcRn g\u00e1tl\u00f3k (IgG lebont\u00e1s), FcR blokkol\u00e1s<\/td><\/tr><tr><td>IL-6\/JAK-STAT3<\/td><td>IL-6, IL-6R\u03b1, gp130, JAK1\/2, STAT3, ROR\u03b3t<\/td><td>Th17 differenci\u00e1l\u00f3d\u00e1s, B-sejt \u00e9r\u00e9s, IgG termel\u00e9s<\/td><td>Anti-IL-6R (tocilizumab, satralizumab)<\/td><\/tr><tr><td>PI3K\/AKT\/MAPK (B-sejtek)<\/td><td>BTK, PI3K, AKT, ERK, NFAT<\/td><td>B-sejt aktiv\u00e1ci\u00f3, plazmasejt \u00e9r\u00e9s<\/td><td>BTK-g\u00e1tl\u00f3k (ibrutinib, tolebrutinib)<\/td><\/tr><tr><td>Th17 citokin h\u00e1l\u00f3zat<\/td><td>IL-17, IL-21, IL-22, GM-CSF, CXCL13<\/td><td>BBB-k\u00e1rosod\u00e1s, leukocit\u00e1k toborz\u00e1sa, demielin\u00e1ci\u00f3<\/td><td>Anti-IL-17, Anti-IL-21<\/td><\/tr><tr><td>FcRn-IgG \u00fajrahasznos\u00edt\u00e1sa<\/td><td>FcRn (\u00fajsz\u00fcl\u00f6ttkori Fc-receptor)<\/td><td>Meghosszabb\u00edtott IgG felez\u00e9si id\u0151<\/td><td>Anti-FcRn (rozanolixizumab)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Relevante_Rezeptoren_und_Zielmolekule\"><\/span>Relev\u00e1ns receptorok \u00e9s c\u00e9lmolekul\u00e1k<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"MOG_selbst_als_Zielstruktur_kein_klassischer_Rezeptor\"><\/span>MOG maga, mint c\u00e9lstrukt\u00fara (nem klasszikus receptor)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>A MOGAD-ban a MOG feh\u00e9rje antig\u00e9nk\u00e9nt, nem pedig jel\u00e1tviteli receptork\u00e9nt m\u0171k\u00f6dik. Mindazon\u00e1ltal a k\u00f6vetkez\u0151 k\u00f6lcs\u00f6nhat\u00e1sok patofiziol\u00f3giai szempontb\u00f3l jelent\u0151sek:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>C1q k\u00f6t\u0151d\u00e9s<\/strong><br>A MOG fiziol\u00f3gi\u00e1san k\u00e9pes C1q-t k\u00f6tni, ami patol\u00f3gi\u00e1s antitestfedetts\u00e9g eset\u00e9n komplementaktiv\u00e1ci\u00f3hoz vezet.<\/li>\n\n\n\n<li><strong>DC-JEL (CD209)<\/strong><br>Lektin receptor a dendritikus sejteken; k\u00e9pes megk\u00f6tni a MOG-ot \u00e9s hozz\u00e1j\u00e1rulni az antig\u00e9n prezent\u00e1ci\u00f3hoz.<\/li>\n\n\n\n<li><strong>Rubeola v\u00edrus receptor<\/strong>_<br>A MOG a rubeolav\u00edrusok bel\u00e9p\u0151 molekul\u00e1jak\u00e9nt szolg\u00e1l, ami magyar\u00e1zatot adhat a gyermekek poszt-infekt\u00edv ADEM-\u00e9re.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Fc%CE%B3-Rezeptoren_Fc%CE%B3R\"><\/span>Fc\u03b3 receptorok (Fc\u03b3R)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Az immunsejtek Fc\u03b3-receptorai az IgG1-medi\u00e1lt k\u00e1rosod\u00e1s k\u00f6zponti effektorai:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Fc\u03b3RI (CD64)<\/strong><br>Nagy affinit\u00e1s, makrof\u00e1gokon \u00e9s dendritikus sejteken; az ADCP \u00e9s az antig\u00e9n prezent\u00e1ci\u00f3 k\u00f6zvet\u00edt\u00e9se<\/li>\n\n\n\n<li><strong>Fc\u03b3RIII (CD16)<\/strong><br>Alacsony affinit\u00e1s\u00fa, NK sejteken; a MOG-opszon\u00e1lt oligodendrocit\u00e1k elleni ADCC f\u0151 k\u00f6zvet\u00edt\u0151je.<\/li>\n\n\n\n<li><strong>Fc\u03b3RIIA\/B (CD32A\/B)<\/strong><br>Aktiv\u00e1l\u00e1s vagy g\u00e1tl\u00e1s; a B-sejtek aktiv\u00e1l\u00e1s\u00e1nak \u00e9s fagocit\u00f3zis\u00e1nak modul\u00e1l\u00e1sa<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Neonataler_Fc-Rezeptor_FcRn\"><\/span>\u00dajsz\u00fcl\u00f6ttkori Fc-receptor (FcRn)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Az FcRn (\u03b22m\/FcRn-\u03b1 komplex) felel\u0151s az IgG antitestek intracellul\u00e1ris \u00fajrahasznos\u00edt\u00e1s\u00e1\u00e9rt. A savas endosz\u00f3m\u00e1kban (pH 6,0) megk\u00f6ti az IgG-t \u00e9s megakad\u00e1lyozza annak lizoszom\u00e1lis leboml\u00e1s\u00e1t, ez\u00e1ltal az IgG felez\u00e9si ideje kb. 21 napra n\u0151.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>A MOGAD-ban az FcRn okozza a patog\u00e9n MOG-IgG1 tart\u00f3s kering\u00e9s\u00e9t.<\/li>\n\n\n\n<li>Ter\u00e1pi\u00e1s blokkol\u00e1s a k\u00f6vetkez\u0151k miatt <em>Rozanolixizumab<\/em> (anti-FcRn IgG4): K\u00e9nyszer\u00edti a lizoszom\u00e1lis IgG lebont\u00e1st \u00e9s cs\u00f6kkenti a plazma IgG-t ~50%-vel.<\/li>\n\n\n\n<li>FcRn expresszi\u00f3 - h\u00e1msejtek, endot\u00e9lsejtek, monocit\u00e1k, hepatocit\u00e1k<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"IL-6-Rezeptor_IL-6R%CE%B1_gp130\"><\/span>IL-6 receptor (IL-6R\u03b1 \/ gp130)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Az IL-6 receptor a ligandumot k\u00f6t\u0151 \u03b1-alegys\u00e9gb\u0151l (IL-6R\u03b1, CD126) \u00e9s a jel\u00e1tviteli t\u00e1rsreceptor gp130-b\u00f3l (IL-6R\u03b2, CD130) \u00e1ll. K\u00e9t szign\u00e1l\u00e1si m\u00f3d:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Klasszikus jelz\u00e9s<\/strong><br>Membr\u00e1nhoz k\u00f6t\u00f6tt IL-6R\u03b1 a T-sejteken, B-sejteken, monocit\u00e1kon \u2192 IL-6\/IL-6R\u03b1\/gp130 komplex \u2192 JAK1\/2 \u2192 STAT3, STAT1, MAPK, PI3K\/AKT<\/li>\n\n\n\n<li><strong>Transz-jelz\u00e9s<\/strong><br>Az oldhat\u00f3 IL-6R\u03b1 (sIL-6R) megk\u00f6ti az IL-6-ot \u00e9s aktiv\u00e1lja a gp130-at m\u00e9g a membr\u00e1nhoz k\u00f6t\u00f6tt IL-6R\u03b1 n\u00e9lk\u00fcli sejteken is (pl. a BBB endot\u00e9lsejtjei).<\/li>\n<\/ul>\n\n\n\n<p>Relev\u00e1ns downstream hat\u00e1sok: (Th17), Bcl-6 (Tfh \u00e9s cs\u00edracentrumok), Blimp-1 (plazmasejtek), FoxP3 szuppresszi\u00f3ja (Treg).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"T-Zell-Rezeptor_TCR_und_Kostimulationsmolekule\"><\/span>T-sejt receptor (TCR) \u00e9s kosztimul\u00e1ci\u00f3s molekul\u00e1k<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>TCR\/MHC-II-MOG peptidkomplexum<\/strong><br>A MOG-specifikus CD4+ T-sejtek k\u00f6zponti aktiv\u00e1ci\u00f3s tengelye<\/li>\n\n\n\n<li><strong>CD28\/B7<\/strong><br>Kosztimul\u00e1ci\u00f3 a T-sejtek aktiv\u00e1ci\u00f3ja sor\u00e1n<\/li>\n\n\n\n<li><strong>CCR6\/CCL20 tengely<\/strong><br>A Th17 sejtek CCR6-ja a CCL20-hoz k\u00f6t\u0151dik a plexus chorioideusban \u2192 CNS bejut\u00e1s<\/li>\n\n\n\n<li><strong>CXCR3\/CXCL10<\/strong><br>A Th1 sejtek kemotaxisa a gyullad\u00e1sos ter\u00fcleteken<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Komplementrezeptoren\"><\/span>Komplement receptorok<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>C1qR<\/strong><br>K\u00f6zvet\u00edti a C1q k\u00f6t\u0151d\u00e9s\u00e9t az oligodendrocita membr\u00e1nokon l\u00e9v\u0151 immunkomplexekhez.<\/li>\n\n\n\n<li><strong>C3aR <\/strong>\u00e9s<strong> C5aR1 (CD88)<\/strong><br>Anafilatoxin receptorok a mikroglia\/makrof\u00e1gokon \u2192 Proinflammatorikus aktiv\u00e1ci\u00f3<\/li>\n\n\n\n<li><strong>Az oligodendrocit\u00e1k komplement szab\u00e1lyoz\u00f3i<\/strong><br>A CR1 (CD35), MCP (CD46), HRF (CD59) alacsonyan expressz\u00e1l\u00f3dik az oligodendrocit\u00e1kon, ami \u00e9rz\u00e9kenyebb\u00e9 teszi \u0151ket a komplement k\u00e1rosod\u00e1s\u00e1ra, mint p\u00e9ld\u00e1ul az asztrocit\u00e1kat.<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Histopathologie_und_ZNS-Lasionsmuster\"><\/span>Hisztopatol\u00f3gia \u00e9s a CNS elv\u00e1ltoz\u00e1s mint\u00e1zata<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p>A MOGAD-elv\u00e1ltoz\u00e1sok sz\u00f6vettanilag alapvet\u0151en k\u00fcl\u00f6nb\u00f6znek az MS-t\u0151l \u00e9s az NMOSD-t\u0151l:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Perivenosus demyeliniz\u00e1ci\u00f3<\/strong><br>Az elv\u00e1ltoz\u00e1sok koncentrikusan alakulnak ki a kis v\u00e9n\u00e1k k\u00f6r\u00fcl (periven\u00f3zus mint\u00e1zat), nem pedig periaxi\u00e1lisan, mint az SM-ben. Az MS-re jellemz\u0151 \u201ak\u00f6zponti v\u00e9n\u00e1s jel\u2018 hi\u00e1nyzik az MRI-n.<\/li>\n\n\n\n<li><strong>CD4+ T-sejtes infiltr\u00e1tum<\/strong><br>Domin\u00e1ns gyullad\u00e1sos sejtmint\u00e1zat a CD4+ T-sejtek \u00e9s makrof\u00e1gok, kevesebb neutrofil \u00e9s alig eozinofil granulocita (ellent\u00e9tben az AQP4+ NMOSD-vel).<\/li>\n\n\n\n<li><strong>Oligodendrocita k\u00e1rosod\u00e1s<\/strong> (els\u0151dleges)<br>Az NMOSD-vel ellent\u00e9tben, ahol els\u0151sorban az asztrocit\u00e1k k\u00e1rosodnak, a MOGAD-ot oligodendrocita degener\u00e1ci\u00f3 jellemzi.<\/li>\n\n\n\n<li><strong>C9neo lerak\u00f3d\u00e1s<\/strong><br>MAC (termin\u00e1lis komplementkomplex) kimutat\u00e1sa az elv\u00e1ltoz\u00e1sokban, b\u00e1r gyeng\u00e9bb, mint az NMOSD-ben.<\/li>\n\n\n\n<li><strong>Relat\u00edv axon konzerv\u00e1ci\u00f3<\/strong><br>Az akut rohamokban az axon\u00e1lis k\u00e1rosod\u00e1s gyakran kev\u00e9sb\u00e9 s\u00falyos, mint a szkler\u00f3zis multiplexben, ami magyar\u00e1zza a gyakran j\u00f3 klinikai gy\u00f3gyul\u00e1st.<\/li>\n\n\n\n<li><strong>Kortik\u00e1lis elv\u00e1ltoz\u00e1sok<\/strong><br>Leptomeninge\u00e1lis gyullad\u00e1s \u00e9s agyk\u00e9rgi demyeliniz\u00e1ci\u00f3 (gyakori az ADEM-v\u00e1ltozatban)<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Klinische_Manifestationen_und_Phanotypen\"><\/span>Klinikai megnyilv\u00e1nul\u00e1sok \u00e9s fenot\u00edpusok<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p>A MOGAD klinikailag heterog\u00e9n. Fontos fenot\u00edpusok:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Fenot\u00edpus<\/strong><\/td><td><strong>Frekvencia<\/strong><\/td><td><strong>Klinikai jellemz\u0151k<\/strong><\/td><td><strong>MRI szakter\u00fcletek<\/strong><\/td><\/tr><\/thead><tbody><tr><td>Optikai neuritisz (ON)<\/td><td>Leggyakoribb (kb. 50%)<\/td><td>Gyakran k\u00e9toldali, l\u00e1t\u00e1sveszt\u00e9s, retrobulb\u00e1ris, f\u00e1jdalmas szemmozg\u00e1sok. szemmozg\u00e1sok<\/td><td>Hossz\u00fa l\u00e1t\u00f3ideg \u00e9rintetts\u00e9g, kontrasztanyag-felhalmoz\u00f3d\u00e1s a l\u00e1t\u00f3ideg k\u00f6r\u00fcl.<\/td><\/tr><tr><td>Transzverz\u00e1lis myelitis<\/td><td>Kb. 30%<\/td><td>Longitudin\u00e1lis myelitis (LETM), szenzoros\/motoros, h\u00f3lyagzavarok<\/td><td>Longitudin\u00e1lis T2 elv\u00e1ltoz\u00e1sok, H2-szindr\u00f3ma (\u201alencs\u00e9s\u2018)<\/td><\/tr><tr><td>ADEM<\/td><td>Leggyakoribb megnyilv\u00e1nul\u00e1s gyermekekn\u00e9l<\/td><td>Enkefalop\u00e1tia, polifok\u00e1lis neurol\u00f3giai hi\u00e1nyoss\u00e1gok deficitek<\/td><td>K\u00e9toldali, nagy t\u00e9rfogat\u00fa T2 elv\u00e1ltoz\u00e1sok, szint\u00e9n a baz\u00e1lis ganglionokn\u00e1l.<\/td><\/tr><tr><td>Agyt\u00f6rzsi agyvel\u0151gyullad\u00e1s<\/td><td>Kb. 15%<\/td><td>Diplopia, ataxia, area postrema szindr\u00f3ma (csukl\u00e1s, h\u00e1ny\u00e1s)<\/td><td>Agyt\u00f6rzsi \/ kisagyi T2 elv\u00e1ltoz\u00e1sok<\/td><\/tr><tr><td>Kortik\u00e1lis agyvel\u0151gyullad\u00e1s<\/td><td>Ritk\u00e1bb<\/td><td>Epilepszi\u00e1s rohamok, zavarts\u00e1g<\/td><td>Kortik\u00e1lis FLAIR jel\u00e1tviteli v\u00e1ltoz\u00e1sok<\/td><\/tr><tr><td>CRION<\/td><td>Ritk\u00e1bb<\/td><td>Kr\u00f3nikus visszat\u00e9r\u0151 gyullad\u00e1s. Optikai neurop\u00e1tia<\/td><td>Tart\u00f3s l\u00e1t\u00f3ideg-k\u00e1rosod\u00e1s<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Diagnostik\"><\/span>Diagnosztika<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p>Diagnosztikai krit\u00e9riumok (Banwell et al, <em>Lancet Neurology<\/em> 2023) sz\u00fcks\u00e9ges: <\/p>\n\n\n\n<p>(1) A MOG-IgG kimutat\u00e1sa sz\u00e9rumban vagy liquorban sejtalap\u00fa teszttel (CBA)<br>(2) megfelel\u0151 klinikai fenot\u00edpus<br>(3) Alternat\u00edv diagn\u00f3zisok kiz\u00e1r\u00e1sa.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sejt-alap\u00fa immunfluoreszcencia teszt (CBA)<\/strong><br>term\u00e9szetes m\u00f3don \u00f6sszehajtott, membr\u00e1nhoz k\u00f6t\u00f6tt MOG-gal (hum\u00e1n MOG-gal transzfekt\u00e1lt HEK293 sejtek); konform\u00e1ci\u00f3f\u00fcgg\u0151 epit\u00f3pokat mutat ki.<\/li>\n\n\n\n<li><strong>ELISA \u00e9s line\/strip blotok<\/strong><br>Megb\u00edzhatatlan a MOGAD eset\u00e9ben, mivel line\u00e1ris epit\u00f3pokat ismernek fel.<\/li>\n\n\n\n<li><strong>IgG aloszt\u00e1lyok<\/strong><br>Els\u0151sorban IgG1; esetenk\u00e9nt IgG2, IgG3, IgG4. A kiz\u00e1r\u00f3lagos IgG3 pozitivit\u00e1s diagnosztikai buktat\u00f3 (Jarius 2024)<\/li>\n\n\n\n<li><strong>Titre kinetika<\/strong><br>A tart\u00f3san magas titerek korrel\u00e1lnak a visszaes\u00e9s kock\u00e1zat\u00e1val; gyakran cs\u00f6kken\u0151 monof\u00e1zisos lefoly\u00e1s eset\u00e9n.<\/li>\n\n\n\n<li><strong>Szeszes italok<\/strong><br>Pleocit\u00f3zis lehets\u00e9ges; oligoclon\u00e1lis s\u00e1vok ritk\u00e1k (&lt;10 %), intrathec\u00e1lis IgG szint\u00e9zis ritka.<\/li>\n\n\n\n<li><strong>Biomarkerek<\/strong><br>sNfL (sz\u00e9rum neurofilamentum k\u00f6nny\u0171 l\u00e1nc) mint a betegs\u00e9g aktivit\u00e1s\u00e1nak markere; sGFAP (gli\u00e1lis fibrill\u00e1ris savas feh\u00e9rje) mint az asztrocit\u00e1k \u00e9rintetts\u00e9g\u00e9nek markere.<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Therapeutische_Strategien\"><\/span>Ter\u00e1pi\u00e1s strat\u00e9gi\u00e1k<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Akuttherapie_Schubbehandlung\"><\/span>Akut ter\u00e1pia (visszaes\u00e9s kezel\u00e9se)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>A MOGAD visszaes\u00e9s\u00e9nek szok\u00e1sos kezel\u00e9se:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Magasan adagolt <em>Metilprednizolon<\/em> (HDMP)<\/strong><br>1000 mg i.v. naponta 5 napig - els\u0151 vonalban<\/li>\n\n\n\n<li><em><strong>Plazmaferezis \/ immunoadszorpci\u00f3<\/strong><\/em><br>El\u00e9gtelen HDMP-v\u00e1lasz eset\u00e9n; elt\u00e1vol\u00edtja a MOG-IgG-t a plazm\u00e1b\u00f3l; 5-7 ciklus (retrospekt\u00edv adatok szerint az esetek kb. 50-70%-\u00e9ben hat\u00e1sos).<\/li>\n\n\n\n<li><strong><em>Intrav\u00e9n\u00e1s immunglobulinok<\/em> (IVIG)<\/strong><br>2 g\/kg 5 napon kereszt\u00fcl; HDMP-re adott v\u00e1lasz hi\u00e1ny\u00e1ban \u00e9s plazmaferezis ut\u00e1ni lehet\u0151s\u00e9gk\u00e9nt; val\u00f3sz\u00edn\u0171leg az FcRn tel\u00edtetts\u00e9g \u00e9s az Fc\u03b3R-konkurencia r\u00e9v\u00e9n hat\u00e9kony.<\/li>\n\n\n\n<li><strong>A kortikoszteroidok szed\u00e9s\u00e9nek cs\u00f6kkent\u00e9se<\/strong><br>K\u00fcl\u00f6n\u00f6sen fontos a MOGAD (gyakori szteroidf\u00fcgg\u0151s\u00e9g) eset\u00e9ben - a gyors cs\u00f6kkent\u00e9s visszaes\u00e9si epiz\u00f3dokat v\u00e1lthat ki.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Prophylaktische_Langzeittherapie\"><\/span>Profilaktikus hossz\u00fa t\u00e1v\u00fa ter\u00e1pia<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>(off-label, nincs enged\u00e9lyezett k\u00e9sz\u00edtm\u00e9ny - 2026-os st\u00e1tusz)<\/p>\n\n\n\n<p>A hossz\u00fa t\u00e1v\u00fa ter\u00e1pia indik\u00e1ci\u00f3ja egy\u00e9nre szabott - nem minden betegnek van r\u00e1 sz\u00fcks\u00e9ge. T\u00e9nyez\u0151k: visszaes\u00e9si ar\u00e1ny, a visszaes\u00e9sek s\u00falyoss\u00e1ga, tart\u00f3s MOG-IgG-titerek, fenot\u00edpusos kock\u00e1zati t\u00e9nyez\u0151k.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Anyag<\/strong><\/td><td><strong>A hat\u00e1smechanizmus<\/strong><\/td><td><strong>Adatok helyzete<\/strong><\/td><td><strong>A bizony\u00edt\u00e9kok szintje<\/strong><\/td><\/tr><\/thead><tbody><tr><td>Azatioprin<\/td><td>Purinszint\u00e9zis-blok\u00e1d (TPMT-f\u00fcgg\u0151); g\u00e1tolja a T- \u00e9s B-sejtek prolifer\u00e1ci\u00f3j\u00e1t.<\/td><td>Retrospekt\u00edv vizsg\u00e1latok; nemzeti RCT folyamatban (Franciaorsz\u00e1g, TOMATO tanulm\u00e1ny)<\/td><td>IIb-III (off-label)<\/td><\/tr><tr><td>Miofenol\u00e1t-mofetil (MMF)<\/td><td>Inozin-monofoszf\u00e1t-dehidrogen\u00e1z inhibitor; g\u00e1tolja a limfocit\u00e1k prolifer\u00e1ci\u00f3j\u00e1t.<\/td><td>Esetsorozat; val\u00f3sz\u00edn\u0171leg hat\u00e9kony, a rituximabn\u00e1l alacsonyabb relapszusmegel\u0151z\u00e9s<\/td><td>III (off-label)<\/td><\/tr><tr><td>Rituximab<\/td><td>Anti-CD20 \u2192 B-sejt-depl\u00e9ci\u00f3; g\u00e1tolja a MOG-IgG termel\u00e9st<\/td><td>Legnagyobb retrospekt\u00edv kohorsz; hat\u00e9kony, de nem mindenkin\u00e9l; fokozott fert\u0151z\u00e9svesz\u00e9ly.<\/td><td>IIb (off-label)<\/td><\/tr><tr><td>Tocilizumab<\/td><td>Anti-IL-6R\u03b1 (iv); blokkolja az IL-6 jel\u00e1tviteli \u00fatvonalat (JAK\/STAT3); g\u00e1tolja a Th17\/plazmasejteket<\/td><td>Pozit\u00edv retrospekt\u00edv adatok; az NMOSD-re vonatkoz\u00f3 RCT eredm\u00e9nyek pozit\u00edvak (TANGO).<\/td><td>IIb (off-label)<\/td><\/tr><tr><td>IVIG (iv\/szubkut\u00e1n)<\/td><td>Fc-receptor tel\u00edtetts\u00e9g; MOG-IgG semleges\u00edt\u00e9s; FcRn tel\u00edtetts\u00e9g<\/td><td>Visszamen\u0151leges adatok pozit\u00edvak; lehet\u0151s\u00e9g a term\u00e9kenys\u00e9gre, terhess\u00e9gre, fert\u0151z\u00e9sre vonatkoz\u00f3an<\/td><td>IIb (off-label)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Klinische_Studien_%E2%80%93_2024%E2%80%932026\"><\/span>Klinikai vizsg\u00e1latok - 2024-2026<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>A MOGAD eset\u00e9ben most el\u0151sz\u00f6r t\u00f6bb randomiz\u00e1lt, placebo-kontroll\u00e1lt 3. f\u00e1zis\u00fa vizsg\u00e1lat van folyamatban, amelyek v\u00e1rhat\u00f3an I. oszt\u00e1ly\u00fa bizony\u00edt\u00e9kot szolg\u00e1ltatnak:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Tanulm\u00e1ny<\/strong><\/td><td><strong>Anyag<\/strong><\/td><td><strong>Mechanizmus<\/strong><\/td><td><strong>C\u00e9lcsoport<\/strong><\/td><td><strong>\u00c1llapot<\/strong><\/td><\/tr><\/thead><tbody><tr><td>cosMOG<\/td><td>Rozanolixizumab (UCB7665)<\/td><td>Anti-FcRn IgG4-mAb: blokkolja az IgG \u00fajrahasznos\u00edt\u00e1st \u2192 felgyors\u00edtja az IgG leboml\u00e1s\u00e1t, cs\u00f6kkenti a MOG IgG titer\u00e9t ~50 %<\/td><td>Feln\u0151ttek (\u226518 \u00e9vesek), visszaes\u0151, \u22651 visszaes\u00e9s\/12 h\u00f3nap<\/td><td>3. f\u00e1zis\u00fa, nemzetk\u00f6zi; az els\u0151 MOGAD 3. f\u00e1zis\u00fa vizsg\u00e1lat<\/td><\/tr><tr><td>METEOROID<\/td><td>Satralizumab (anti-IL-6R sc.)<\/td><td>Anti-IL-6R (szubkut\u00e1n); g\u00e1tolja a JAK\/STAT3 \u2192 Th17 differenci\u00e1l\u00f3d\u00e1s, B-sejt \u00e9r\u00e9s, IgG termel\u00e9s.<\/td><td>Feln\u0151ttek + serd\u00fcl\u0151k (\u226512 \u00e9vesek); visszaes\u0151 betegek, akiket legal\u00e1bb 1 visszaes\u00e9s el\u0151z\u00f6tt meg.<\/td><td>3. f\u00e1zis, nemzetk\u00f6zi, folyamatban<\/td><\/tr><tr><td>TOMATO<\/td><td>Azatioprin<\/td><td>Purinszint\u00e9zis g\u00e1tl\u00e1s; sz\u00e9les k\u00f6rben immunszuppressz\u00edv<\/td><td>Francia multicentrikus vizsg\u00e1lat; MOGAD-ban szenved\u0151 feln\u0151ttek<\/td><td>Nemzeti RCT, 3. f\u00e1zis<\/td><\/tr><tr><td>MOGwAI<\/td><td>Nincs meghat\u00e1rozva (megfigyel\u00e9s)<\/td><td>Biomarker-vizsg\u00e1lat: a MOG-IgG-titer, sNfL, sGFAP, sCD83 mint progresszi\u00f3s markerek valid\u00e1l\u00e1sa.<\/td><td>Nemzetk\u00f6zi kohorszvizsg\u00e1lat<\/td><td>Folyamatos<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Neue_und_zukunftige_Therapiekonzepte\"><\/span>\u00daj \u00e9s j\u00f6v\u0151beli ter\u00e1pi\u00e1s koncepci\u00f3k<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Az elm\u00falt \u00e9vek molekul\u00e1ris eredm\u00e9nyei alapj\u00e1n a MOGAD k\u00f6vetkez\u0151 megk\u00f6zel\u00edt\u00e9seit t\u00e1rgyaljuk:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"BTK-Inhibitoren_Bruton-Tyrosin-Kinase\"><\/span>BTK-g\u00e1tl\u00f3k (Bruton-tirozinkin\u00e1z)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>A BTK a B-sejt receptor szign\u00e1l kaszk\u00e1d (PI3K\/AKT\/MAPK) k\u00f6zponti kin\u00e1za. <strong><em>Tolebrutinib<\/em><\/strong> \u00e9s m\u00e1s BTK-g\u00e1tl\u00f3k az MS \u00e9s NMOSD kutat\u00e1s\u00e1ban vannak; a MOGAD eset\u00e9ben klinikai vizsg\u00e1latok folyamatban vannak. Az or\u00e1lis alkalmaz\u00e1s el\u0151ny\u00f6s lenne. Mind a B-sejtek aktiv\u00e1ci\u00f3j\u00e1nak, mind a myeloid sejtek (mikroglia-BTK) g\u00e1tl\u00e1sa.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Toleranzinduktion_MOG-Tolerisierung\"><\/span>Tolerancia indukci\u00f3 (MOG-tolerancia)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Az antig\u00e9nspecifikus tolerancia indukci\u00f3 (pl. MOG peptidek vagy nanor\u00e9szecske-alap\u00fa megk\u00f6zel\u00edt\u00e9sek r\u00e9v\u00e9n) \u00edg\u00e9retes koncepci\u00f3. A <strong><em>Guthy-Jackson J\u00f3t\u00e9konys\u00e1gi Alap\u00edtv\u00e1ny<\/em><\/strong> El\u0151seg\u00edti a gy\u00f3gy\u00edt\u00f3 megk\u00f6zel\u00edt\u00e9sek kutat\u00e1s\u00e1t. El\u0151ny: Nincs glob\u00e1lis immunszuppresszi\u00f3, <strong>A MOG autoreaktivit\u00e1s szelekt\u00edv megsz\u00fcntet\u00e9se<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Komplementinhibitoren\"><\/span>Komplement-g\u00e1tl\u00f3k<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Mivel a komplementaktiv\u00e1ci\u00f3 (C3a, C5a, MAC) kimutathat\u00f3 a MOGAD-elv\u00e1ltoz\u00e1sokban, ez\u00e9rt az lenne <strong><em>Eculizumab<\/em> (Anti-C5)<\/strong> vagy egy C3-g\u00e1tl\u00f3 elm\u00e9letileg hat\u00e1sos. Mivel azonban a MAC-komplex (C5b-9) sokkal kisebb m\u00e9rt\u00e9kben k\u00e9pz\u0151dik a MOGAD-ban, mint az NMOSD-ben (ahol <em>Eculizumab<\/em> enged\u00e9lyezett), a klinikai relevancia bizonytalan.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Anti-Neonatal-Fc-Rezeptor-Strategien\"><\/span>Anti-neonatalis Fc receptor strat\u00e9gi\u00e1k<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>A  mellett <em>Rozanolixizumab<\/em> is <strong><em>Efgartigimod<\/em><\/strong> (egy IgG-Fc fragmentum, amely kompetit\u00edvan blokkolja az FcRn-t) m\u00e1s IgG-medi\u00e1lt betegs\u00e9gekre. Mivel az FcRn-blok\u00e1d patomechanizmusa k\u00f6zvetlen\u00fcl cs\u00f6kkenti a MOG-IgG-szintet, ez egy k\u00fcl\u00f6n\u00f6sen c\u00e9lzott megk\u00f6zel\u00edt\u00e9s.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Autologe_hamatopoetische_Stammzelltransplantation_aHSCT\"><\/span>Autol\u00f3g v\u00e9rk\u00e9pz\u0151 \u0151ssejt-transzplant\u00e1ci\u00f3 (aHSCT)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>S\u00falyos, refrakter lefoly\u00e1s\u00fa k\u00f3rfolyamatok eset\u00e9n az aHSCT potenci\u00e1lisan gy\u00f3gy\u00edt\u00f3 koncepci\u00f3: a m\u00e9ly immunoabl\u00e1ci\u00f3 \u00e9s az immunrendszer rekonstrukci\u00f3ja megsz\u00fcntetheti az autoreakt\u00edv T- \u00e9s B-sejtkl\u00f3nokat. A MOGAD-ra vonatkoz\u00f3an nagyon korl\u00e1tozott adatok \u00e1llnak rendelkez\u00e9sre; csak speci\u00e1lis k\u00f6zpontokban alkalmazhat\u00f3.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Biomarker_und_Verlaufsmonitoring\"><\/span>Biomarkerek \u00e9s nyomon k\u00f6vet\u00e9s<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p>A jelenlegi kutat\u00e1sok c\u00e9lja a biomarker-alap\u00fa ter\u00e1pi\u00e1s d\u00f6nt\u00e9sek meghozatala:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MOG-IgG-titer (sz\u00e9rum)<\/strong><br>A perzisztencia korrel\u00e1l a visszaes\u00e9s kock\u00e1zat\u00e1val; monof\u00e1zisos lefoly\u00e1s eset\u00e9n gyakran spont\u00e1n cs\u00f6kken a titer; a ter\u00e1pi\u00e1s d\u00f6nt\u00e9s t\u00e1rsmeghat\u00e1roz\u00f3.<\/li>\n\n\n\n<li><strong>Sz\u00e9rum neurofilamentum f\u00e9ny (sNfL)<\/strong><br>Az axon\u00e1lis k\u00e1rosod\u00e1s markere; relapszus idej\u00e9n emelkedik; normaliz\u00e1l\u00f3dik, mint ter\u00e1pi\u00e1s v\u00e1laszmarker.<\/li>\n\n\n\n<li><strong>Sz\u00e9rum GFAP (sGFAP)<\/strong><br>Asztrocita aktiv\u00e1ci\u00f3; alacsonyabb a MOGAD-ban, mint az NMOSD-ben; kieg\u00e9sz\u00edt\u0151 inform\u00e1ci\u00f3t ny\u00fajthat<\/li>\n\n\n\n<li><strong>sCD83<\/strong><br>\u00daj jel\u00f6lt biomarker (valid\u00e1l\u00e1s alatt); val\u00f3sz\u00edn\u0171leg a dendritikus sejtek aktiv\u00e1l\u00f3d\u00e1s\u00e1nak \u00e9s az immunaktivit\u00e1snak a markere.<\/li>\n\n\n\n<li><strong>Cerebrospin\u00e1lis folyad\u00e9k sejtsz\u00e1m \u00e9s feh\u00e9rje<\/strong><br>Pleocit\u00f3zis a tol\u00f3er\u0151k alatt; normaliz\u00e1l\u00f3d\u00e1s a ter\u00e1pia ut\u00e1n<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Prognose_und_Besonderheiten\"><\/span>El\u0151rejelz\u00e9s \u00e9s k\u00fcl\u00f6nlegess\u00e9gek<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p>Az AQP4+ NMOSD-vel \u00f6sszehasonl\u00edtva a MOGAD ink\u00e1bb egy <strong>Kedvez\u0151bb el\u0151rejelz\u00e9s<\/strong>, k\u00fcl\u00f6n\u00f6sen jobb vizu\u00e1lis helyre\u00e1ll\u00edt\u00e1s az ON ut\u00e1n. A k\u00f6vetkez\u0151 szempontok azonban fontosak:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Monof\u00e1zisos progresszi\u00f3<\/strong><br>A betegek kb. 50%-je; gyakran spont\u00e1n cs\u00f6kken a titer; hossz\u00fa t\u00e1v\u00fa ter\u00e1pia nem felt\u00e9tlen\u00fcl sz\u00fcks\u00e9ges.<\/li>\n\n\n\n<li><strong>Tol\u00f3er\u0151-alak\u00fa progresszi\u00f3<\/strong><br>Kb. 50%; a magasabb titer megmarad; kumulat\u00edv rokkants\u00e1g kialakul\u00e1sa lehets\u00e9ges, de lassabb, mint az NMOSD-n\u00e9l.<\/li>\n\n\n\n<li><strong>Nincs progressz\u00edv tanfolyam<\/strong><br>A szkler\u00f3zis multiplexszel ellent\u00e9tben nem \u00edrtak le fokozatos, relapszusok n\u00e9lk\u00fcli progresszi\u00f3t.<\/li>\n\n\n\n<li><strong>Szteroid\u00e9rz\u00e9kenys\u00e9g \u00e9s szteroidf\u00fcgg\u0151s\u00e9g<\/strong><br>Sok beteg azonban nagyon j\u00f3l reag\u00e1l a kortikoszteroidokra: a gyors cs\u00f6kkent\u00e9s gyakran v\u00e1lt ki visszaes\u00e9st.<\/li>\n\n\n\n<li><strong>K\u00fcl\u00f6nleges gyermekgy\u00f3gy\u00e1szati funkci\u00f3<\/strong><br>ADEM a leggyakoribb kezdeti manifeszt\u00e1ci\u00f3 gyermekekn\u00e9l (&lt;10 \u00e9v); a progn\u00f3zis gyakran j\u00f3, de meg kell jegyezni a ki\u00fajul\u00e1s kock\u00e1zat\u00e1t.<\/li>\n\n\n\n<li><strong>Terhess\u00e9g: v\u00e9kony adatok<\/strong><br>A terhess\u00e9g alatt nincs \u00e1ltal\u00e1nosan megn\u00f6vekedett visszaes\u00e9s kock\u00e1zata, de a sz\u00fcl\u00e9s ut\u00e1ni id\u0151szak kock\u00e1zati t\u00e9nyez\u0151 lehet (az MS-hez hasonl\u00f3an).<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Zusammenfassung_und_Ausblick\"><\/span>\u00d6sszefoglal\u00f3 \u00e9s kil\u00e1t\u00e1sok<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p>A MOGAD a k\u00f6zponti idegrendszer f\u00fcggetlen, antitest-k\u00f6zvet\u00edtett autoimmun betegs\u00e9ge, amelyet a k\u00f6vetkez\u0151 f\u0151 jellemz\u0151k jellemeznek:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Az oligodendrocit\u00e1k \u00e9s a mielinh\u00fcvelyek k\u00fcls\u0151 oldal\u00e1n tal\u00e1lhat\u00f3 MOG feh\u00e9rje a c\u00e9lantig\u00e9n.<\/li>\n\n\n\n<li>A patog\u00e9n MOG-IgG1 autoantitestek k\u00e9t p\u00e1rhuzamos effektor \u00fatvonalon kereszt\u00fcl k\u00e1ros\u00edtj\u00e1k a mielint: komplement aktiv\u00e1ci\u00f3 (CDC, kb. 50%) \u00e9s Fc\u03b3R k\u00f6t\u0151d\u00e9s (ADCC\/ADCP, kb. 50%).<\/li>\n\n\n\n<li>Ezenk\u00edv\u00fcl az antitestek az Fc\u03b3R mechanizmusokon kereszt\u00fcl er\u0151s\u00edtik a T-sejtek aktiv\u00e1l\u00f3d\u00e1s\u00e1t.<\/li>\n\n\n\n<li>Az IL-6\/JAK\/STAT3 jel\u00e1tviteli \u00fatvonal el\u0151seg\u00edti a Th17 differenci\u00e1l\u00f3d\u00e1st \u00e9s a plazmasejtek \u00e9r\u00e9s\u00e9t, \u00e9s kulcsfontoss\u00e1g\u00fa ter\u00e1pi\u00e1s c\u00e9lpontot k\u00e9pez<\/li>\n\n\n\n<li>Jelenleg nincs enged\u00e9lyezett ter\u00e1pia (2026. febru\u00e1r 20-\u00e1n); az els\u0151 3. f\u00e1zis\u00fa RCT-k folyamatban vannak (cosMOG rozanolixizumabbal, METEOROID szatralizumabbal).<\/li>\n\n\n\n<li>A ter\u00e1pia a kock\u00e1zathoz igazod\u00f3, biomarker-alap\u00fa strat\u00e9gi\u00e1k ir\u00e1ny\u00e1ba mozdul el.<\/li>\n<\/ul>\n\n\n\n<p>Az ut\u00f3bbi \u00e9vek legfontosabb kutat\u00e1si el\u0151rel\u00e9p\u00e9se az effektor mechanizmusok (komplement vs. FcR \u00fatvonal) pontos dek\u00f3dol\u00e1sa volt, amelyet olyan kutat\u00f3csoportok v\u00e9geztek, mint p\u00e9ld\u00e1ul a k\u00f6vetkez\u0151 kutat\u00f3csoportok <strong>Meinl, Mader, Kawakami (LMU M\u00fcnchen)<\/strong>, ami k\u00f6zvetlen hat\u00e1ssal van a ter\u00e1pia fejleszt\u00e9s\u00e9re: Az optim\u00e1lis ter\u00e1pi\u00e1s megk\u00f6zel\u00edt\u00e9snek az IgG-termel\u00e9sre (anti-CD20, FcRn-g\u00e1tl\u00f3k), valamint az effektor mechanizmusokra (komplement, Fc\u03b3R) \u00e9s a Th17\/IL-6 tengelyre kell ir\u00e1nyulnia.<\/p>\n\n\n\n<p>A toleranciaindukci\u00f3s strat\u00e9gi\u00e1k \u00e9s a BTK-g\u00e1tl\u00f3k olyan j\u00f6v\u0151beli, mechanisztikailag megalapozott ter\u00e1pi\u00e1s elveket k\u00e9pviselnek, amelyeket az elk\u00f6vetkez\u0151 \u00e9vekben val\u00f3sz\u00edn\u0171leg klinikai kipr\u00f3b\u00e1lnak.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Atherischer_Ole_%E2%80%93_Wirkstoffe_nach_Signalwegen_geordnet\"><\/span>Ill\u00f3olajok - hat\u00f3anyagok jel\u00e1tviteli \u00fatvonalak szerint rendezve<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>A hat\u00f3anyagok a MOGAD patofiziol\u00f3gi\u00e1j\u00e1ban a t\u00e1mad\u00e1si pontjaik szerint csoportos\u00edthat\u00f3k. Ez az\u00e9rt kulcsfontoss\u00e1g\u00fa, mert a MOGAD-nak h\u00e1rom f\u0151 tengelye van: <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Th17\/IL-6<\/strong><\/li>\n\n\n\n<li><strong>Komplement rendszer\/oligodendrocita v\u00e9delem<\/strong><\/li>\n\n\n\n<li><strong>Remyeliniz\u00e1ci\u00f3\/OPC differenci\u00e1l\u00f3d\u00e1s<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Weihrauch_Boswellia_serrata_%E2%80%93_AKBA_und_Incensolacetat\"><\/span>Frankincense (Boswellia serrata) - AKBA \u00e9s incensol-acet\u00e1t<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>A BCP szerint ez a MOGAD tudom\u00e1nyosan legmegalapozottabb jel\u00f6ltje, \u00e9s kiv\u00e9teles a hat\u00e1sspektrum\u00e1t tekintve.<\/p>\n\n\n\n<p><strong>AKBA (3-O-acetil-11-keto-\u03b2-boszwelinsav)<\/strong> a f\u0151 hat\u00f3anyag. Az AKBA-nak sz\u00e1mos \u00e9lettani hat\u00e1sa van, bele\u00e9rtve a fert\u0151z\u00e9sellenes, daganatellenes \u00e9s antioxid\u00e1ns hat\u00e1sokat, valamint a bizony\u00edtott neuroprotekt\u00edv hat\u00e1sokat. El\u0151seg\u00edti az idegek helyre\u00e1ll\u00edt\u00e1s\u00e1t \u00e9s regener\u00e1l\u00f3d\u00e1s\u00e1t, v\u00e9d az ischaemi\u00e1s agyk\u00e1rosod\u00e1s ellen, g\u00e1tolja a neuroinflamm\u00e1ci\u00f3t \u00e9s jav\u00edtja a mem\u00f3riazavarokat. <a href=\"https:\/\/www.ean.org\/research\/resources\/neurology-updates\/detail\/complement-dependent-and-independent-pathomechanisms-of-myelin-oligodendrocyte-glycoprotein-mog-abs-implications-for-therapeutic-strategies-in-mog-antibody-associated-disease-mogad\" target=\"_blank\" rel=\"noreferrer noopener\">Eur\u00f3pai Neurol\u00f3giai Akad\u00e9mia<\/a><\/p>\n\n\n\n<p><strong>Az AKBA g\u00e1tolja a STAT3 m\u0171k\u00f6d\u00e9s\u00e9t<\/strong> d\u00f3zisf\u00fcgg\u0151, ami kulcsfontoss\u00e1g\u00fa mechanizmus, mivel a STAT3 a Th17 differenci\u00e1l\u00f3d\u00e1st \u00e9s a plazmasejtek \u00e9r\u00e9s\u00e9t ir\u00e1ny\u00edt\u00f3 IL-6\/JAK jel\u00e1tviteli \u00fatvonal f\u0151 transzkripci\u00f3s faktora a MOGAD-ban. Ezenk\u00edv\u00fcl az Nrf2\/HO-1 jel\u00e1tviteli \u00fatvonal AKBA \u00e1ltali aktiv\u00e1l\u00e1sa az oxidat\u00edv k\u00e1rosod\u00e1s cs\u00f6kkent\u00e9s\u00e9nek, a demielin\u00e1ci\u00f3 megel\u0151z\u00e9s\u00e9nek \u00e9s a remielin\u00e1ci\u00f3 el\u0151seg\u00edt\u00e9s\u00e9nek ir\u00e1ny\u00e1t adja. <a href=\"https:\/\/pubs.acs.org\/doi\/10.1021\/acs.nanolett.9b02220\" target=\"_blank\" rel=\"noreferrer noopener\">ACS kiadv\u00e1nyok<\/a><\/p>\n\n\n\n<p>Az AKBA olyan molekul\u00e1ris kapcsol\u00f3k\u00e9nt m\u0171k\u00f6dik, amely az 5-LOX \u00e9s a 15-LOX alloszt\u00e9rikus modul\u00e1ci\u00f3j\u00e1n kereszt\u00fcl g\u00e1tolja a leukotri\u00e9nk\u00e9pz\u0151d\u00e9st, ugyanakkor serkenti az SPM (Specialised Pro-Resolving Mediators - specializ\u00e1lt pro-rezolving medi\u00e1torok) termel\u00e9s\u00e9t. Ez akt\u00edvan eltolja az immunv\u00e1laszt az al\u00e1bbiak ir\u00e1ny\u00e1ba <strong>A gyullad\u00e1s felold\u00e1sa<\/strong>, nem csak a csillap\u00edt\u00e1suk. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39133885\/\" target=\"_blank\" rel=\"noreferrer noopener\">PubMed<\/a><\/p>\n\n\n\n<p><strong>Incensol-acet\u00e1t<\/strong> (a t\u00f6mj\u00e9n ill\u00f3olaj ill\u00e9kony \u00f6sszetev\u0151je, el\u0151fordul BHS) aktiv\u00e1lja a TRPV3 csatorn\u00e1kat az idegsejtekben, valamint a PPAR-\u03b3-t - A t\u00f6mj\u00e9n \u00f6sszetev\u0151i jelent\u0151sen cs\u00f6kkenthetik az IL-6, TNF-\u03b1 \u00e9s GFAP (az asztrocita aktiv\u00e1ci\u00f3 markere) mennyis\u00e9g\u00e9t az agyban az induk\u00e1lt gyullad\u00e1st k\u00f6vet\u0151en. <a href=\"https:\/\/www.neurology.org\/doi\/10.1212\/NXI.0000000000200293\" target=\"_blank\" rel=\"noreferrer noopener\">Neurol\u00f3gia<\/a><\/p>\n\n\n\n<p><strong>Fontos min\u0151s\u00e9gi megjegyz\u00e9s:<\/strong> A Boswellia term\u00e9kek k\u00f6z\u00f6tt jelent\u0151s min\u0151s\u00e9gi k\u00fcl\u00f6nbs\u00e9gek vannak, egyes term\u00e9kek (pl. H15 Ayurmedica\u00ae) az elemz\u00e9sek sor\u00e1n csak nyomokban tartalmazz\u00e1k a jellegzetes boswelliasavakat (0,31 mg AKBA). Ezzel szemben az olyan term\u00e9kek, mint a BOSWELLIASAN\u00ae (7,51 mg) \u00e9s a Sallaki\u00ae tabletta (7,88 mg) jelent\u0151s mennyis\u00e9g\u0171 AKBA-t \u00e9s ennek megfelel\u0151en er\u0151s farmakol\u00f3giai hat\u00e1st mutattak ki. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34358086\/\" target=\"_blank\" rel=\"noreferrer noopener\">A boszwelinsav-tartalom elemz\u00e9se \u00e9s a gyullad\u00e1st modul\u00e1l\u00f3, t\u00f6mj\u00e9n alap\u00fa gy\u00f3gym\u00f3dok kapcsol\u00f3d\u00f3 farmakol\u00f3giai tev\u00e9kenys\u00e9gei<\/a> \u00e9s <a href=\"https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2025.1530977\/full\" target=\"_blank\" rel=\"noreferrer noopener\">Hat\u00e1rok<\/a>.<\/p>\n\n\n\n<p>A doTERRA term\u00e9k <strong><a href=\"https:\/\/media.doterra.com\/us\/en\/pips\/frankincense-boswellic-acid-complex.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Frankincense Boswellic Acid Complex<\/a><\/strong> 37,5 mg AKBA-t tartalmaz*<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Therapeutisch_relevante_AKBA-Zieldosen\"><\/span>Ter\u00e1pi\u00e1san relev\u00e1ns AKBA c\u00e9ld\u00f3zisok<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>A klinikai \u00e9s preklinikai kutat\u00e1sokb\u00f3l a k\u00f6vetkez\u0151 k\u00e9p rajzol\u00f3dik ki:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Az alkalmaz\u00e1s c\u00e9lja<\/th><th>AKBA napi adag<\/th><th>Forr\u00e1s<\/th><\/tr><\/thead><tbody><tr><td>Gyullad\u00e1scs\u00f6kkent\u0151 (\u00e1ltal\u00e1nos)<\/td><td>100-200 mg<\/td><td>Emberi tanulm\u00e1nyok \u00edz\u00fclet\/b\u00e9l<\/td><\/tr><tr><td>NF-\u03baB \/ STAT3 g\u00e1tl\u00e1s (neuroinflamm\u00e1ci\u00f3)<\/td><td>200-400 mg<\/td><td>\u00c1llati modellek, sejtkult\u00fara<\/td><\/tr><tr><td>Optim\u00e1lis CNS-hat\u00e1s (barrier passage)<\/td><td>200-300 mg<\/td><td>K\u00eds\u00e9rleti adatok<\/td><\/tr><tr><td>Fels\u0151 j\u00f3l toler\u00e1lt napi adag<\/td><td>400-600 mg<\/td><td>Tolerancia vizsg\u00e1latok<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Umrechnung_auf_375_mg_AKBA_jeKapsel\"><\/span>\u00c1tv\u00e1lt\u00e1s 37,5 mg AKBA-ra kapszul\u00e1nk\u00e9nt<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>C\u00e9l-AKBA napi adag<\/th><th>Egys\u00e9g\/nap<\/th><th>Gyakorlati s\u00e9ma<\/th><\/tr><\/thead><tbody><tr><td>150 mg<\/td><td>4 egys\u00e9g<\/td><td>2 \u00d7 reggel + 2 \u00d7 este<\/td><\/tr><tr><td>200 mg<\/td><td><strong>5-6 egys\u00e9g<\/strong><\/td><td>3 \u00d7 reggel + 2-3 \u00d7 este<\/td><\/tr><tr><td>300 mg<\/td><td>8 egys\u00e9g<\/td><td>4 \u00d7 reggel + 4 \u00d7 este<\/td><\/tr><tr><td>400 mg<\/td><td>10-11 egys\u00e9g<\/td><td>3 \u00d7 3-4 egys\u00e9g naponta<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Aj\u00e1nlott bejegyz\u00e9s:<\/strong> <strong>4 egys\u00e9g naponta (= 150 mg AKBA)<\/strong>, 2 aj\u00e1nd\u00e9kra osztva.<\/p>\n\n\n\n<p>2 h\u00e9t eltelt\u00e9vel - ha j\u00f3l toler\u00e1lhat\u00f3 - n\u00f6velje 6 egys\u00e9gre (= 225 mg).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wichtige_Einnahmehinweise\"><\/span>Fontos felv\u00e9teli utas\u00edt\u00e1sok<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>A zs\u00edr d\u00f6nt\u0151 fontoss\u00e1g\u00fa:<\/strong> Az AKBA er\u0151sen lipofil, a <strong>A biol\u00f3giai hozz\u00e1f\u00e9rhet\u0151s\u00e9g 2-3-szoros\u00e1ra n\u0151<\/strong>, ha zs\u00edros \u00e9tkez\u00e9ssel egy\u00fctt veszik be. Ide\u00e1lis az ol\u00edvaolaj, az avok\u00e1d\u00f3 vagy a f\u0151\u00e9tkez\u00e9s. Az \u00e9hgyomorra t\u00f6rt\u00e9n\u0151 bev\u00e9tel drasztikusan cs\u00f6kkenti a felsz\u00edv\u00f3d\u00e1st.<\/p>\n\n\n\n<p><strong>Id\u0151z\u00edt\u00e9s:<\/strong> Az AKBA felez\u00e9si ideje kb. 6 \u00f3ra, ez\u00e9rt <strong>2-3 adag naponta<\/strong> Ennek t\u00f6bb \u00e9rtelme van, mint az egyszeri adagol\u00e1snak az egyenletes hat\u00e9konys\u00e1gi szint fenntart\u00e1sa \u00e9rdek\u00e9ben.<\/p>\n\n\n\n<p><strong>BCP-vel kombin\u00e1lva:<\/strong> Az AKBA (STAT3\/NF-\u03baB tengely) \u00e9s a BCP (CB2\/Th17 tengely) a MOGAD k\u00fcl\u00f6nb\u00f6z\u0151 jel\u00e1tviteli \u00fatvonalait c\u00e9lozza, \u00e9s szinergikusan hat. Farmakol\u00f3giai k\u00f6lcs\u00f6nhat\u00e1sok nem ismertek.<\/p>\n\n\n\n<p><strong>Gyomort\u0171r\u00e9s:<\/strong> A Boswellia \u00e1ltal\u00e1ban nagyon j\u00f3l toler\u00e1lhat\u00f3. Enyhe gyomorirrit\u00e1ci\u00f3 ritk\u00e1n fordul el\u0151 nagyobb adagokn\u00e1l. Ez\u00e9rt mindig \u00e9tkez\u00e9s k\u00f6zben vegye be, vagy sz\u00fcks\u00e9g eset\u00e9n \u00e1tmenetileg cs\u00f6kkentse az adagot.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Schwarzer_Pfeffer_oral\"><\/span>Fekete bors (sz\u00e1jon \u00e1t)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>A feketebors-olaj f\u0151 hat\u00f3anyaga a \u03b2-karyophil\u00e9n (BCP) (<em>Piper nigrum<\/em>) a gyullad\u00e1sos citokinek IL-6, TNF-\u03b1, IL-17, IFN-\u03b3 \u00e9s a Th17 (ROR-\u03b3t) \u00e9s Th1 (T-bet) transzkripci\u00f3s faktorok cs\u00f6kken\u00e9s\u00e9t, valamint a gyullad\u00e1scs\u00f6kkent\u0151 citokinek TGF-\u03b21, IL-10, IL-4 \u00e9s a Th2 (GATA3) \u00e9s Treg (Foxp3) transzkripci\u00f3s faktorok jelent\u0151s n\u00f6veked\u00e9s\u00e9t okozza. Ezek a hat\u00e1sok szigor\u00faan a CB2 receptor aktiv\u00e1l\u00e1s\u00e1hoz kapcsol\u00f3dnak.<\/p>\n\n\n\n<p>A CB2-receptorok \u00e9s a remieliniz\u00e1ci\u00f3 mechanisztikailag k\u00f6zvetlen\u00fcl kapcsol\u00f3dnak egym\u00e1shoz: a CB2-agonizmus el\u0151seg\u00edti az OPC-k \u00e9r\u00e9s\u00e9t - egy \u00faj gener\u00e1ci\u00f3s CB2-agonista (Yhhu4952) szignifik\u00e1nsan n\u00f6velte a myelin alapfeh\u00e9rje (MBP) expresszi\u00f3j\u00e1t \u00e9s az \u00e9rett oligodendrocit\u00e1k ar\u00e1ny\u00e1t a corpus callosumban.<\/p>\n\n\n\n<p>Fekete bors adagol\u00e1sa: 20 ... 200 mg\/d - ami 20 tr.\/d-nek felel meg - \u00edgy a legjobb, ha 7 trp. 8 \u00f3r\u00e1nk\u00e9nt (a magasabb plazmaszintekhez lehet\u0151leg 5 trp. 6 \u00f3r\u00e1nk\u00e9nt) viv\u0151olajban, kapszul\u00e1ban szedj\u00fck. Lipofilk\u00e9nt magas zs\u00edrtartalm\u00fa \u00e9tellel\/itallal egy\u00fctt.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Schwarzer_Pfeffer_Inhalation\"><\/span>Fekete bors (inhal\u00e1l\u00e1s)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Adagol\u00e1s: Napk\u00f6zben 4 \u00f3r\u00e1nk\u00e9nt 3 trp. bel\u00e9legezve (felez\u00e9si id\u0151 2-4 \u00f3ra) a f\u0171t\u00f6tt diff\u00fazor Liqui-Padj\u00e1ra 20 percig, \u00e9s minden m\u00e9ly bel\u00e9gz\u00e9s ut\u00e1n 5-8 m\u00e1sodpercig tartsa vissza a l\u00e9legzet\u00e9t, \u00e9jszaka hagyja a diff\u00fazort a szob\u00e1ban futni, k\u00f6zvetlen bel\u00e9gz\u00e9s nem megengedett.<\/p>\n\n\n\n<p>A fekete borsnak serkent\u0151 hat\u00e1sa lehet, \u00e9s ronthatja az alv\u00e1st. Ebben az esetben ne diffund\u00e1ljon \u00e9jszaka.<\/p>\n\n\n\n<p>Ha a l\u00e9gutak irrit\u00e1l\u00f3dnak (sz\u00e1razs\u00e1g) vagy fejf\u00e1j\u00e1s alakul ki: Cs\u00f6kkentse az adagot vagy n\u00f6velje az intervallumokat.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Copaiba-Ol_oral_%E2%80%93_NUR_doTERRA\"><\/span>Copaiba olaj (sz\u00e1jon \u00e1t) - CSAK doTERRA<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>52,6 % BCP - 14,7 mg BCP\/cseppnek felel meg - mivel a BCP lipofil, mindig magas zs\u00edrtartalm\u00fa \u00e9telhez\/italhoz kell bevenni!<\/p>\n\n\n\n<p>A klinikai biztons\u00e1gi vizsg\u00e1latok szerint ez a k\u00f6vetkez\u0151 adagol\u00e1si aj\u00e1nl\u00e1st eredm\u00e9nyezi a tests\u00faly alapj\u00e1n:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"MOGAD-spezifische_Dosierungstabelle_doTERRA_Copaiba_525_BCP\"><\/span>MOGAD-specifikus adagol\u00e1si t\u00e1bl\u00e1zat (doTERRA Copaiba 52.5 % BCP)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Tests\u00faly<\/th><th><strong>Meg\u0151rz\u00e9s<\/strong> (0,4 mg\/kg)<\/th><th><strong>Akt\u00edv tol\u00f3er\u0151<\/strong> (1,0 mg\/kg)<\/th><th><strong>Intenz\u00edv ter\u00e1pia<\/strong> (1,5 mg\/kg)<\/th><\/tr><\/thead><tbody><tr><td><strong>50 kg<\/strong><\/td><td>20 mg = <strong>1-2 csepp<\/strong><\/td><td>50 mg = <strong>3-4 csepp<\/strong><\/td><td>75 mg = <strong>5 csepp<\/strong><\/td><\/tr><tr><td><strong>60 kg<\/strong><\/td><td>24 mg = <strong>2 csepp<\/strong><\/td><td>60 mg = <strong>4 csepp<\/strong><\/td><td>90 mg = <strong>6 csepp<\/strong><\/td><\/tr><tr><td><strong>70 kg<\/strong><\/td><td>28 mg = <strong>2 csepp<\/strong><\/td><td>70 mg = <strong>5 csepp<\/strong><\/td><td>105 mg = <strong>7 csepp<\/strong><\/td><\/tr><tr><td><strong>80 kg<\/strong><\/td><td>32 mg = <strong>2 csepp<\/strong><\/td><td>80 mg = <strong>5-6 csepp<\/strong><\/td><td>120 mg = <strong>8 csepp<\/strong><\/td><\/tr><tr><td><strong>90 kg<\/strong><\/td><td>36 mg = <strong>2-3 csepp<\/strong><\/td><td>90 mg = <strong>6 csepp<\/strong><\/td><td>135 mg = <strong>9 csepp<\/strong><\/td><\/tr><tr><td><strong>100 kg<\/strong><\/td><td>40 mg = <strong>3 csepp<\/strong><\/td><td>100 mg = <strong>7 csepp<\/strong><\/td><td>150 mg = <strong>10 csepp<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"MOGAD-Phasen-adaptierte_Dosierung\"><\/span>MOGAD f\u00e1zishoz igaz\u00edtott adagol\u00e1s<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_1_Akuter_Schub_erste_2%E2%80%934_Wochen\"><\/span><strong>1. f\u00e1zis: Akut fell\u00e1ngol\u00e1s (els\u0151 2-4 h\u00e9t)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>C\u00e9lpont:<\/strong> Agressz\u00edv Th17 szuppresszi\u00f3, IL-6 cs\u00f6kkent\u00e9s<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Adagol\u00e1s:<\/strong> 1,0-1,5 mg\/kg naponta<\/li>\n\n\n\n<li><strong>Div\u00edzi\u00f3:<\/strong> 3\u00d7 naponta (optim\u00e1lis a CB2 receptor folyamatos aktiv\u00e1l\u00e1s\u00e1hoz)<\/li>\n\n\n\n<li><strong>P\u00e9lda 70 kg:<\/strong> 5-7 csepp naponta, 2+2+3 cseppenk\u00e9nt elosztva<\/li>\n\n\n\n<li><strong>Kombin\u00e1ci\u00f3:<\/strong> AKBA-val (200-300 mg\/nap a STAT3 g\u00e1tl\u00e1s\u00e1ra) + nagy d\u00f3zis\u00fa kortizon (standard)<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_2_Schubremission_Erhaltung_langfristig\"><\/span><strong>2. f\u00e1zis: visszaes\u00e9s remisszi\u00f3 \/ fenntart\u00e1s (hossz\u00fa t\u00e1v\u00fa)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>C\u00e9lpont:<\/strong> Visszaes\u00e9s megel\u0151z\u00e9se, \u00e1lland\u00f3 gyullad\u00e1scs\u00f6kkent\u0151 t\u00f3nus<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Adagol\u00e1s:<\/strong> 0,4-0,7 mg\/kg naponta<\/li>\n\n\n\n<li><strong>Div\u00edzi\u00f3:<\/strong> 2\u00d7 naponta<\/li>\n\n\n\n<li><strong>P\u00e9lda 70 kg:<\/strong> 2-3 csepp naponta, 1+2 vagy 2+2 adagban elosztva<\/li>\n\n\n\n<li><strong>Kombin\u00e1ci\u00f3:<\/strong> AKBA-val (150 mg\/nap) opcion\u00e1lis<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_3_Monophasischer_Verlauf_Titer_fallend\"><\/span><strong>3. f\u00e1zis: Monof\u00e1zisos k\u00fara (cs\u00f6kken\u0151 titer)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>C\u00e9lpont:<\/strong> Neuroprotekci\u00f3, remielin\u00e1ci\u00f3<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Adagol\u00e1s:<\/strong> 0,2-0,4 mg\/kg naponta<\/li>\n\n\n\n<li><strong>Div\u00edzi\u00f3:<\/strong> 1-2\u00d7 naponta<\/li>\n\n\n\n<li><strong>P\u00e9lda 70 kg:<\/strong> 1-2 csepp naponta<\/li>\n\n\n\n<li><strong>Kiegyenl\u00edt\u00e9s lehets\u00e9ges<\/strong> 6-12 h\u00f3napos stabil szeronegativit\u00e1s ut\u00e1n<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Quellen\"><\/span>Forr\u00e1sok<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Toxikol\u00f3gia (700 mg\/kg NOAEL)<\/strong><br><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/27358239\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/27358239\/<\/a><\/li>\n\n\n\n<li><strong>EAE modell (2,5-5 mg\/kg hat\u00e1sos)<\/strong><br><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10377147\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10377147\/<\/a><\/li>\n\n\n\n<li><strong>Hum\u00e1n vizsg\u00e1lat (100 mg biztons\u00e1gos)<\/strong><br><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9104399\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9104399\/<\/a><\/li>\n\n\n\n<li><strong>Klinikai vizsg\u00e1lat (126 mg\/nap hat\u00e1sos)<\/strong><br><a href=\"https:\/\/accurateclinic.com\/accurate-education-terpenes-caryophyllene\/\" target=\"_blank\" rel=\"noopener\">https:\/\/accurateclinic.com\/accurate-education-terpenes-caryophyllene\/<\/a><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Copaiba-Ol_Inhalation\"><\/span>Copaiba olaj (inhal\u00e1ci\u00f3)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>A legfeljebb 38% BCP-t tartalmaz\u00f3 fekete bors mellett az ak\u00e1r 87% BCP-t tartalmaz\u00f3 kopaibaolaj sokkal er\u0151sebb, ez\u00e9rt inhal\u00e1l\u00e1sra a legjobb v\u00e1laszt\u00e1s.<br>A diff\u00fazorok \u00e1ltal\u00e1ban hideg ultrahangos (US) porlaszt\u00e1ssal m\u0171k\u00f6dnek. A BCP azonban csak 130 \u00b0C k\u00f6r\u00fcl p\u00e1rolog, \u00e9s 180 \u00b0C feletti h\u0151m\u00e9rs\u00e9kleten \u00e9g el. Ez\u00e9rt f\u0171thet\u0151, h\u0151m\u00e9rs\u00e9klet-szab\u00e1lyozott diff\u00fazorokat kell haszn\u00e1lni (pl. <a href=\"https:\/\/storz-bickel.com\" target=\"_blank\" rel=\"noreferrer noopener\">Volcano Classic, Volcano Hybrid vagy Mighty+<\/a>) a kb. 270-415 eur\u00f3s \u00e1rkateg\u00f3ri\u00e1ban, \u00e9s a h\u0151m\u00e9rs\u00e9kletet a lehet\u0151 legpontosabban (IR-h\u0151m\u00e9r\u0151vel ellen\u0151rizve) 160 \u00b0C-ra kell be\u00e1ll\u00edtani.<\/p>\n\n\n\n<p>A Copaiba olaj (doTERRA) aj\u00e1nlott adagol\u00e1sa 69 % BCP-tartalommal - 1 csepp 18,6 mg BCP-t tartalmaz.<\/p>\n\n\n\n<p>A BCP felez\u00e9si ideje 2-4 \u00f3ra. A hat\u00f3anyag min\u00e9l \u00e1lland\u00f3bb szintj\u00e9nek el\u00e9r\u00e9se \u00e9rdek\u00e9ben az inhal\u00e1ci\u00f3t a fent le\u00edrtak szerint kell v\u00e9gezni 4 \u00f3r\u00e1nk\u00e9nt 4 cseppel (kb. 200 mg BCP-nek megfelel\u0151). Egy diff\u00fazor az \u00e9jszaka folyam\u00e1n az \u00e1gy k\u00f6zel\u00e9ben hagyhat\u00f3.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Zieldosen_und_benotigte_Tropfenzahl\"><\/span>C\u00e9ladagok \u00e9s a sz\u00fcks\u00e9ges cseppek sz\u00e1ma<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>BCP c\u00e9ld\u00f3zis<\/th><th>Csepp Copaiba olaj<\/th><th>\u00d6sszes olaj (mg)<\/th><\/tr><\/thead><tbody><tr><td>20 mg BCP (kezd\u0151 adag)<\/td><td><strong>~1 csepp<\/strong><\/td><td>~29 mg<\/td><\/tr><tr><td>50 mg BCP<\/td><td><strong>~3 csepp<\/strong><\/td><td>~72 mg<\/td><\/tr><tr><td>100 mg BCP (ter\u00e1pi\u00e1s)<\/td><td><strong>~5-6 csepp<\/strong><\/td><td>~145 mg<\/td><\/tr><tr><td>120 mg BCP (fels\u0151 napi adag)<\/td><td><strong>~6-7 csepp<\/strong><\/td><td>~174 mg<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>C\u00e9lzottan bel\u00e9legzett BCP<\/th><th>Az olaj mennyis\u00e9ge a foly\u00e9kony padon<\/th><th>Cseppek<\/th><\/tr><\/thead><tbody><tr><td>~20 mg BCP inhal\u00e1lva<\/td><td>~40 mg olaj (~78 mg\/0,69)<\/td><td><strong>2-3 csepp<\/strong><\/td><\/tr><tr><td>~50 mg BCP inhal\u00e1lva<\/td><td>~100 mg olaj<\/td><td><strong>4-5 csepp<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Synergistische_MOGAD-Strategie_Multi-Target\"><\/span>Szinergikus MOGAD-strat\u00e9gia (t\u00f6bbc\u00e9l\u00fa)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Mivel a MOGAD-nak h\u00e1rom patomechanizmusa van, ez a bizony\u00edt\u00e9kokon alapul\u00f3 kombin\u00e1ci\u00f3 eredm\u00e9nyezi:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Akt\u00edv \u00f6sszetev\u0151<\/th><th>D\u00f3zis<\/th><th>Jel\u00fatvonal<\/th><th>MOGAD relevancia<\/th><\/tr><\/thead><tbody><tr><td><strong>BCP (sz\u00e1jon \u00e1t)<\/strong><\/td><td>0,4-1,5 mg\/kg<\/td><td>CB2 \u2192 Th17\u2193, IL-6\u2193, Nrf2\/HO-1\u2191<\/td><td>\u2605\u2605\u2605\u2605\u2605<\/td><\/tr><tr><td><strong>AKBA (sz\u00e1jon \u00e1t)<\/strong><\/td><td>200-400 mg\/nap<\/td><td>STAT3\u2193, NF-\u03baB\u2193, 5-LOX\u2193<\/td><td>\u2605\u2605\u2605\u2605\u2605<\/td><\/tr><tr><td><strong>BCP (bel\u00e9legezve, 160 \u00b0C)<\/strong><\/td><td>2-3 csepp, 2\u00d7\/nap<\/td><td>Limbikus, gyors CNS penetr\u00e1ci\u00f3<\/td><td>\u2605\u2605\u2605<\/td><\/tr><tr><td><strong>Frankincense olaj (bel\u00e9legezve)<\/strong><\/td><td>3-4 csepp, 2\u00d7\/nap<\/td><td>Incensol-acet\u00e1t \u2192 TRPV3, PPAR-\u03b3<\/td><td>\u2605\u2605\u2605<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Ez a n\u00e9gypill\u00e9res strat\u00e9gia a k\u00f6vetkez\u0151kkel foglalkozik:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Th17\/IL-6<\/strong> (BCP sz\u00e1jon \u00e1t + AKBA)<\/li>\n\n\n\n<li><strong>STAT3<\/strong> (AKBA)<\/li>\n\n\n\n<li><strong>Oligodendrocita v\u00e9delem<\/strong> (BCP Nrf2 aktiv\u00e1l\u00e1s)<\/li>\n\n\n\n<li><strong>Limbikus modul\u00e1ci\u00f3<\/strong> (bel\u00e9gz\u00e9s)<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wichtige_MOGAD-spezifische_Hinweise\"><\/span>Fontos MOGAD-specifikus inform\u00e1ci\u00f3k<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Nincs monoter\u00e1pia<\/strong> - BCP\/AKBA <strong>A hagyom\u00e1nyos ter\u00e1pia kieg\u00e9sz\u00edt\u00e9se<\/strong><br>(kortizon akut, sz\u00fcks\u00e9g eset\u00e9n rituximab\/MMF\/IVIG profilaktikus) - soha nem helyettes\u00edthet\u0151.<\/li>\n\n\n\n<li><strong>Biomarker-monitoroz\u00e1s:<\/strong>\n<ul class=\"wp-block-list\">\n<li>MOG-IgG-titer 3-6 havonta<\/li>\n\n\n\n<li>sNfL (Neurofilament Light) mint aktivit\u00e1si marker<\/li>\n\n\n\n<li>Fontolja meg az adag cs\u00f6kkent\u00e9s\u00e9t, ha a titerek tart\u00f3san cs\u00f6kkennek.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Figyelje meg a tol\u00f3er\u0151t<\/strong> - A fert\u0151z\u00e9sek a f\u0151 kiv\u00e1lt\u00f3 okok<br>Fert\u0151z\u00e9s eset\u00e9n sz\u00fcks\u00e9g eset\u00e9n adagolja <strong>\u00e1tmenetileg 1,5 mg\/kg-ra n\u00f6velni<\/strong> (megel\u0151z\u0151)<\/li>\n\n\n\n<li><strong>Copaiba m\u00e1j\u00e9rt\u00e9kei<\/strong> - Ha &gt;1 mg\/kg &gt;3 h\u00f3napig<br>ALT\/AST ellen\u0151rz\u00e9s 3 havonta<\/li>\n\n\n\n<li><strong>Fekete bors alternat\u00edva<\/strong> - Copaiba-\u00e9rdekl\u0151d\u00e9s eset\u00e9n: Fekete borsolaj (25-38 % BCP)<br>Ezut\u00e1n sz\u00e1m\u00edtsuk ki a cseppek sz\u00e1m\u00e1t \u00d7 2<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"%CE%B1-Asaron_Kalmus-Ol_Acorus_calamus_%E2%80%93_direkt_oligodendrozytenprotektiv\"><\/span>\u03b1-Asarone (calamusolaj, <em>Acorus calamus<\/em>) - k\u00f6zvetlen\u00fcl oligodendrocit\u00e1k-v\u00e9d\u0151<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>A kev\u00e9s hat\u00f3anyag egyike a <strong>k\u00f6zvetlen remyeliniz\u00e1ci\u00f3s hat\u00e1s<\/strong> a <em><strong><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37146420\/\" target=\"_blank\" rel=\"noreferrer noopener\">\u03b1-Asaron<\/a><\/strong><\/em>. Jav\u00edtja az \u00e9rett oligodendrocit\u00e1k hipoxia-ischaemi\u00e1t k\u00f6vet\u0151 elveszt\u00e9se mieliniz\u00e1ci\u00f3s zavar\u00e1t a PPAR-\u03b3 asztrocit\u00e1kban t\u00f6rt\u00e9n\u0151 felszab\u00e1lyoz\u00e1sa \u00e9s aktiv\u00e1l\u00e1sa r\u00e9v\u00e9n. Ez n\u00f6veli a GLT-1 glutam\u00e1t-transzporter expresszi\u00f3j\u00e1t, \u00e9s elt\u00e1vol\u00edtja a t\u00falzott glutam\u00e1tot az extracellul\u00e1ris t\u00e9rb\u0151l, amely egy\u00e9bk\u00e9nt glutam\u00e1t-medi\u00e1lt excitotoxicit\u00e1st okozna az OPC-kben, g\u00e1toln\u00e1 differenci\u00e1l\u00f3d\u00e1sukat \u00e9s sejthal\u00e1lt okozna. <a href=\"https:\/\/www.klinikum.uni-heidelberg.de\/neurologische-klinik\/neurologie-und-poliklinik\/forschung\/neuroimmunology\/ag-molekulare-neuroimmunologie\/mog-enzephalomyelitis\" target=\"_blank\" rel=\"noreferrer noopener\">Heidelbergi Egyetemi K\u00f3rh\u00e1z<\/a><\/p>\n\n\n\n<p>PPARy a neurol\u00f3gi\u00e1ban - <a href=\"https:\/\/www.frontiersin.org\/journals\/neuroscience\/articles\/10.3389\/fnins.2022.1060515\/pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Frontiers Szerkeszt\u0151s\u00e9g 2022<\/a><\/p>\n\n\n\n<p><strong>Figyelem!<\/strong> A k\u00e1lmosolaj sz\u00e1rmaz\u00e1s\u00e1t\u00f3l f\u00fcgg\u0151en k\u00fcl\u00f6nb\u00f6z\u0151 mennyis\u00e9gben tartalmaz \u03b2-aszaront, amely mutag\u00e9nnek min\u0151s\u00fcl. Csak a <strong>\u03b2-aszaronmentes tulajdons\u00e1gok<\/strong> (Acorus calamus var. americanus).<\/p>\n\n\n\n<p><strong>A jelenlegi \u00e1llapot szerint (02.2026) a piaci el\u00e9rhet\u0151s\u00e9g nem adott.<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Geraniumol_Pelargonium_graveolens_%E2%80%93_Neuroinflammation_und_NO\"><\/span>Ger\u00e1niumolaj (<em>Pelargonium graveolens<\/em>) - Neuroinflamm\u00e1ci\u00f3 \u00e9s NO<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7922935\/\" rel=\"nofollow noopener\" target=\"_blank\">Ger\u00e1nium olaj<\/a> hasznos lehet neurodegenerat\u00edv betegs\u00e9gekben, ahol a neuroinflamm\u00e1ci\u00f3 a patofiziol\u00f3gia r\u00e9sze.<br>F\u0151 hat\u00f3anyag <em>Citronellol<\/em> magasabb koncentr\u00e1ci\u00f3ban kiv\u00e1l\u00f3 g\u00e1tl\u00f3 hat\u00e1st mutatott az NO-termel\u00e9sre, ahol a komponensek k\u00f6z\u00f6tti szinergikus k\u00f6lcs\u00f6nhat\u00e1sok a d\u00f6nt\u0151ek.<br>A citronellol g\u00e1tolja az NF-\u03baB-t is - ami k\u00f6zvetlen\u00fcl kapcsol\u00f3dik a mikroglia aktiv\u00e1ci\u00f3j\u00e1hoz a MOGAD-ban.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Teebaum-Ol_Melaleuca_alternifolia_%E2%80%93_Mikroglia-Modulation\"><\/span>Teafaolaj (<em>Melaleuca alternifolia<\/em>) - Mikroglia modul\u00e1ci\u00f3<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10350368\/\" target=\"_blank\" rel=\"noreferrer noopener\">Teafaolaj<\/a> \u00e9s f\u0151 \u00f6sszetev\u0151i g\u00e1tolj\u00e1k az AChE-t \u00e9s a BChE-t, valamint a LOX-ot. Az oxidat\u00edv stressz optimaliz\u00e1l\u00e1sa antioxid\u00e1ns tulajdons\u00e1gok, a neuroinflamm\u00e1ci\u00f3 g\u00e1tl\u00e1sa \u00e9s az AChE\/BChE g\u00e1tl\u00e1sa r\u00e9v\u00e9n \u00e1tfog\u00f3 strat\u00e9giak\u00e9nt hat\u00e9konyan hozz\u00e1j\u00e1rulhat a neuron\u00e1lis sejthal\u00e1l megel\u0151z\u00e9s\u00e9hez.<br>A terpinen-4-ol (f\u0151 hat\u00f3anyag) szint\u00e9n specifikusan g\u00e1tolja a mikroglia M1 polariz\u00e1ci\u00f3j\u00e1t.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wirkstoffubersicht_nach_MOGAD-Signalwegen\"><\/span>A hat\u00f3anyagok \u00e1ttekint\u00e9se a MOGAD jel\u00e1tviteli \u00fatvonalak szerint<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Akt\u00edv \u00f6sszetev\u0151<\/th><th>Olajforr\u00e1s<\/th><th>MOGAD jel\u00e1tviteli \u00fatvonal<\/th><th>A bizony\u00edt\u00e9kok er\u0151ss\u00e9ge<\/th><\/tr><\/thead><tbody><tr><td><strong>\u03b2-karyofil\u00e9n (BCP)<\/strong><\/td><td>Fekete bors, Copaiba<\/td><td>CB2 \u2192 Nrf2\/HO-1, PPAR-\u03b3; Th17\u2193, IL-6\u2193<\/td><td>\u2605\u2605\u2605\u2605 (EAE modell)<\/td><\/tr><tr><td><strong>AKBA<\/strong><\/td><td>Frankincense (<em>Boswellia serrata<\/em>)<\/td><td>STAT3\u2193, NF-\u03baB\u2193, 5-LOX\u2193, SPM\u2191, Nrf2\/HO-1\u2191<\/td><td>\u2605\u2605\u2605\u2605 (CNS vizsg\u00e1latok)<\/td><\/tr><tr><td><strong>Incensol-acet\u00e1t<\/strong><\/td><td>Frankincense (ill\u00e9kony r\u00e9sz)<\/td><td>TRPV3, PPAR-\u03b3, IL-6\u2193, GFAP\u2193<\/td><td>\u2605\u2605\u2605\u2605 (\u00e1llati modell)<\/td><\/tr><tr><td><strong>\u03b1-Asaron<\/strong><\/td><td>Calamus (<em>Acorus calamus<\/em>)<\/td><td>PPAR-\u03b3 \u2192 GLT-1\u2191 \u2192 OPC v\u00e9delem, k\u00f6zvetlen remielin\u00e1ci\u00f3<\/td><td>\u2605\u2605\u2605\u2605 (hipoxia modell)<\/td><\/tr><tr><td><strong>Linalool<\/strong><\/td><td>Levendula, citromf\u0171<\/td><td>NMDA modul\u00e1ci\u00f3, SERT, neuroprotektivit\u00e1s<\/td><td>\u2605\u2605\u2605<\/td><\/tr><tr><td><strong>1,8-Cineol<\/strong><\/td><td>Eukaliptusz, rozmaring<\/td><td>AChE-g\u00e1tl\u00e1s, antioxid\u00e1ns<\/td><td>\u2605\u2605\u2605\u2605 (bizony\u00edtottan az agyban)<\/td><\/tr><tr><td><strong>Citronellol<\/strong><\/td><td>Geranium<\/td><td>NO\u2193, NF-\u03baB\u2193, szinergiahat\u00e1sok<\/td><td>\u2605\u2605<\/td><\/tr><tr><td><strong>Terpinen-4-ol<\/strong><\/td><td>Teafa<\/td><td>Mikroglia M1\u2193, LOX\u2193, AChE\u2193<\/td><td>\u2605\u2605<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Quellen_und_weiterfuhrende_Literatur\"><\/span><strong>Forr\u00e1sok \u00e9s tov\u00e1bbi olvasnival\u00f3k<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Banwell B et al - Lancet Neurol. 2023;22:268-282<\/strong> Diagnosztikai krit\u00e9riumok MOGAD<br><strong>PubMed (ingyenes):<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36706773\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/36706773\/<\/a> <br><strong>ScienceDirect (kivonat ingyenes, teljes sz\u00f6veg k\u00f6lts\u00e9gekkel):<\/strong> <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1474442222004318\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1474442222004318<\/a> <br><strong>DOI:<\/strong> <a href=\"https:\/\/doi.org\/10.1016\/S1474-4422(22)00431-8\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.1016\/S1474-4422(22)00431-8<\/a><\/li>\n\n\n\n<li><strong>Mader S et al - PNAS 2023<\/strong> <em>(Megjegyz\u00e9s: dokumentumunkban \u201ePNAS 2024\" n\u00e9ven szerepel - a helyes megjelen\u00e9si \u00e9v 2023 m\u00e1rciusa.)<\/em> Komplement vs. FcR patomechanizmus, LMU M\u00fcnchen<br><strong>PNAS teljes sz\u00f6veg (ingyenes):<\/strong> <a href=\"https:\/\/www.pnas.org\/doi\/10.1073\/pnas.2300648120\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.pnas.org\/doi\/10.1073\/pnas.2300648120<\/a> <br><strong>LMU sajt\u00f3k\u00f6zlem\u00e9ny (magyar\u00e1zattal):<\/strong> <a href=\"https:\/\/www.med.lmu.de\/bmc\/en\/news\/latest-news\/news-overview\/news\/autoimmune-disease-mogad-insights-into-pathomechanisms.html\" target=\"_blank\" rel=\"noopener\">https:\/\/www.med.lmu.de\/bmc\/en\/news\/latest-news\/news-overview\/news\/autoimmune-disease-mogad-insights-into-pathomechanisms.html<\/a> <br><strong>EAN komment\u00e1r:<\/strong> <a href=\"https:\/\/www.ean.org\/research\/resources\/neurology-updates\/detail\/complement-dependent-and-independent-pathomechanisms-of-myelin-oligodendrocyte-glycoprotein-mog-abs-implications-for-therapeutic-strategies-in-mog-antibody-associated-disease-mogad\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.ean.org\/research\/resources\/neurology-updates\/detail\/complement-dependent-and-independent-pathomechanisms-of-myelin-oligodendrocyte-glycoprotein-mog-abs-implications-for-therapeutic-strategies-in-mog-antibody-associated-disease-mogad<\/a> <\/li>\n\n\n\n<li><strong>Kaneko K et al - Neurol Neuroimmunol Neuroinflamm. 2024;11(5):e200293<\/strong> CSF komplement aktiv\u00e1ci\u00f3<br>Az e200293 cikk a k\u00f6vetkez\u0151 <strong>nem tal\u00e1lhat\u00f3 meg k\u00f6zvetlen\u00fcl<\/strong> - A kapcsol\u00f3d\u00f3 MOGAD \u00e1ttekint\u0151 cikk ugyanebb\u0151l a sz\u00e1mb\u00f3l (e200275, Moseley\/Zamvil) azonban el\u00e9rhet\u0151:<br><strong>Neurology NXI (e200275, ugyanebben a sz\u00e1mban):<\/strong> <a href=\"https:\/\/www.neurology.org\/doi\/10.1212\/NXI.0000000000200275\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.neurology.org\/doi\/10.1212\/NXI.0000000000200275<\/a> <br><strong>PubMed keres\u00e9s a Kaneko 2024 MOGAD CSF-re:<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38996203\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/38996203\/<\/a> <em>(az e200275-h\u00f6z vezet - az e200293-hoz k\u00f6zvetlen PubMed-keres\u00e9s aj\u00e1nlott)<\/em><\/li>\n\n\n\n<li><strong>Cho EB et al - Front Immunol. 2024;15:1320094<\/strong> Kieg\u00e9sz\u00edt\u0151 minta MOGAD vs. NMOSD<br><strong>Frontiers (Teljes sz\u00f6veg szabadon):<\/strong> <a href=\"https:\/\/doi.org\/10.3389\/fimmu.2024.1320094\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.3389\/fimmu.2024.1320094<\/a> <em>(DOI k\u00f6zvetlen\u00fcl el\u00e9rhet\u0151)<\/em><\/li>\n\n\n\n<li><strong>Frontiers Immunol. 2025 - EAE modellek, MOGAD patogenezis<\/strong> <em>(A dokumentumban \u00e1ltal\u00e1nosan hivatkozott - ez a jel\u00e1tviteli \u00fatvonalakr\u00f3l\/patomechanizmusokr\u00f3l sz\u00f3l\u00f3 \u00e1ttekint\u0151 cikkre utal.)<\/em><br><strong>Frontiers Immunol. 2025 (Sun et al., PMID 40406135):<\/strong> <a href=\"https:\/\/doi.org\/10.3389\/fimmu.2025.1535571\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.3389\/fimmu.2025.1535571<\/a><\/li>\n\n\n\n<li><strong>PMC 2023 - \u00c1tfog\u00f3 fel\u00fclvizsg\u00e1lat Pathophysiology MOGAD<\/strong><br><strong>PMC Teljes sz\u00f6veg (ingyenes):<\/strong> <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9597055\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9597055\/<\/a><\/li>\n\n\n\n<li><strong>PMC 2024 - Friss\u00edtett \u00e1ttekint\u00e9s Klinikai spektrum, patogenezis, kezel\u00e9s<\/strong><br><strong>PubMed\/PMC (Trewin et al., Autoimmun Rev 2025):<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39577549\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/39577549\/<\/a><br><strong>PMC teljes sz\u00f6veg:<\/strong> <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9294102\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9294102\/<\/a> <em>(Monoklon\u00e1lis antitest ter\u00e1pi\u00e1k NMOSD\/MOGAD)<\/em><\/li>\n\n\n\n<li><strong>St\u00f6gbauer J et al - Autoimmunity Reviews 2025;103970<\/strong> Ter\u00e1pi\u00e1s megk\u00f6zel\u00edt\u00e9sek Feln\u0151ttek MOGAD<br><strong>ScienceDirect (ny\u00edlt hozz\u00e1f\u00e9r\u00e9s, teljes sz\u00f6veg szabadon):<\/strong> <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1568997225002319\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1568997225002319<\/a> <br><strong>DOI:<\/strong> <a href=\"https:\/\/doi.org\/10.1016\/j.autrev.2025.103970\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.1016\/j.autrev.2025.103970<\/a> <br><strong>N\u00e9met nyelv\u0171 \u00f6sszefoglal\u00f3:<\/strong> <a href=\"https:\/\/www.reine-nervensache.de\/therapieansaetze-bei-mogad-von-der-akutbehandlung-zur-langfristigen-strategie\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.reine-nervensache.de\/therapieansaetze-bei-mogad-von-der-akutbehandlung-zur-langfristigen-strategie\/<\/a> <\/li>\n\n\n\n<li><strong>Szak\u00e9rt\u0151i v\u00e9lem\u00e9ny az \u00fajonnan megjelen\u0151 gy\u00f3gyszerekr\u0151l 2025 - Klinikai vizsg\u00e1lati t\u00e1jk\u00e9p<\/strong><br><strong>Tandfonline (kivonat ingyenes, a teljes sz\u00f6veg k\u00f6lts\u00e9gekkel j\u00e1r):<\/strong> <a href=\"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2025.2565189\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2025.2565189<\/a><br><strong>DOI:<\/strong> <a href=\"https:\/\/doi.org\/10.1080\/14728214.2025.2565189\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.1080\/14728214.2025.2565189<\/a><br><\/li>\n\n\n\n<li><strong>NEMOS tanulm\u00e1nyoz\u00f3 csoport<\/strong> <a href=\"https:\/\/www.nemos-net.de\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.nemos-net.de<\/a><br><\/li>\n\n\n\n<li><strong>Betegk\u00f6zpont\u00fa vizsg\u00e1lat \u00e1ttekint\u00e9se (cosMOG\/METEOROID):<\/strong><br>A MOG projekt - <a href=\"https:\/\/mogproject.org\/clinical-trials\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/mogproject.org\/clinical-trials\/<\/a><br>ClinicalTrials.gov - cosMOG - <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05063162\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/clinicaltrials.gov\/study\/NCT05063162<\/a><\/li>\n<\/ul>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>Minden tartalom lelkiismeretesen kutatott, \u00e9s a jelenlegi (02.2026) k\u00f6zz\u00e9tett ismeretanyagot t\u00fckr\u00f6zi. Kiz\u00e1r\u00f3lag t\u00e1j\u00e9koztat\u00f3 jelleg\u0171, \u00e9s nem helyettes\u00edti a szakszer\u0171 orvosi konzult\u00e1ci\u00f3t.<br>Minden adagol\u00e1si aj\u00e1nl\u00e1st egyeztetni kell a kezel\u0151orvossal. <br>A kapcsol\u00f3d\u00f3 tanulm\u00e1nyok tov\u00e1bbi orvosi \u00e9s tudom\u00e1nyos inform\u00e1ci\u00f3kkal l\u00e1tj\u00e1k el a szakembert.<\/p>\n<\/blockquote>","protected":false},"excerpt":{"rendered":"<p><span class=\"span-reading-time rt-reading-time\" style=\"display: block;\"><span class=\"rt-label rt-prefix\">Olvas\u00e1si id\u0151<\/span> <span class=\"rt-time\"> 17<\/span> <span class=\"rt-label rt-postfix\">percek<\/span><\/span>Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Was ist MOGAD? Jeder kennt elektrische Leitungen: Sie sind mit einer Isolierung versehen, die die einzelne Leiter im Kableb\u00fcndel von einander trennt, damit die Signale in ihnen einander nicht st\u00f6ren und unverf\u00e4lscht von A nach B gelangen.Das R\u00fcckenmark beinhaltet einen ganzen Strang vieler solcher Kabelb\u00fcndel. Sie leiten die Nervensignale vom&hellip;&nbsp;<a href=\"https:\/\/csiag.de\/hu\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/\" rel=\"bookmark\">Olvass tov\u00e1bb \"<span class=\"screen-reader-text\">MOGAD - MOG antitestekkel \u00f6sszef\u00fcgg\u0151 betegs\u00e9g<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[1078,354],"tags":[94,5721,5717,5720,5714,5713,5711,5715,5719,5716,77,90,5712,5718],"class_list":["post-12718","post","type-post","status-publish","format-standard","hentry","category-medizin","category-medizin-gesundheit","tag-antikoerper","tag-bcp","tag-glykoprotein","tag-igg","tag-mog","tag-mogad","tag-molekulare-signalwege","tag-myelin","tag-myelinscheide","tag-oligodendrozyten","tag-pathophysiologie","tag-rezeptoren","tag-therapiekonzepte","tag-transmebranprotein"],"modified_by":"Achim Goerner","_links":{"self":[{"href":"https:\/\/csiag.de\/hu\/wp-json\/wp\/v2\/posts\/12718","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/csiag.de\/hu\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csiag.de\/hu\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csiag.de\/hu\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/csiag.de\/hu\/wp-json\/wp\/v2\/comments?post=12718"}],"version-history":[{"count":0,"href":"https:\/\/csiag.de\/hu\/wp-json\/wp\/v2\/posts\/12718\/revisions"}],"wp:attachment":[{"href":"https:\/\/csiag.de\/hu\/wp-json\/wp\/v2\/media?parent=12718"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csiag.de\/hu\/wp-json\/wp\/v2\/categories?post=12718"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csiag.de\/hu\/wp-json\/wp\/v2\/tags?post=12718"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}